{"content":"<li class=\"n-box-item date-title\" data-end=\"1574744399\" data-start=\"1574658000\" data-txt=\"Monday, December 23, 2019\">Monday, November 25, 2019</li><li class=\"n-box-item sa-box-item\" data-id=\"3521955\" data-ts=\"1574726475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARDX\" target=\"_blank\">ARDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521955-ardelyx-wins-new-agreements-20m-equity-investment-from-kyowa-kirin\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ardelyx wins new agreements, $20M equity investment from Kyowa Kirin</a></h4><ul><li>Ardelyx (NASDAQ:<a href='https://seekingalpha.com/symbol/ARDX' title='Ardelyx, Inc.'>ARDX</a>) <font color=\"green\">+9.1%</font> after-hours on news it is <a href=\"https://seekingalpha.com/pr/17710653-ardelyx-kyowa-kirin-expand-partnership-two-additional-agreements\" target=\"_blank\">expanding its partnership</a> with Kyowa Kirin (<a href='https://seekingalpha.com/symbol/KYKOF' title='Kyowa Kirin Co., Ltd.'>OTCPK:KYKOF</a>) through two new agreements and receiving a $20M equity investment from the Japanese biopharma company.</li><li>The companies establish a two-year research collaboration to advance two of ARDX's research programs focused on the identification and design of compounds to two undisclosed targets; Kyowa Kirin will pay $10M to ARDX to support the ongoing research.</li><li>Kyowa Kirin will have the option to license any candidates nominated by the companies for further development and commercialization in certain territories.</li><li>The two companies initially established a partnership in 2017 through a license agreement that provided Kyowa Kirin with exclusive rights to develop and commercialize ARDX's lead investigational product tenapanor for the treatment of cardiorenal diseases in Japan.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521955\" data-linked=\"Ardelyx wins new agreements, $20M equity investment from Kyowa Kirin\" data-tweet=\"$ARDX $KYKOF - Ardelyx wins new agreements, $20M equity investment from Kyowa Kirin https://seekingalpha.com/news/3521955-ardelyx-wins-new-agreements-20m-equity-investment-from-kyowa-kirin?source=tweet\" data-url=\"https://seekingalpha.com/news/3521955-ardelyx-wins-new-agreements-20m-equity-investment-from-kyowa-kirin\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521954\" data-ts=\"1574725007\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KIN\" target=\"_blank\">KIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521954-kindred-bio-wins-fda-approval-of-zimeta-for-control-of-equine-pyrexia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kindred Bio wins FDA approval of Zimeta for control of equine pyrexia</a></h4><ul><li>Kindred Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/KIN' title='Kindred Biosciences, Inc.'>KIN</a>) <font color=\"green\">+8.8%</font> after-hours on news the Food and Drug Administration's Center for Veterinary Medicine <a href=\"https://seekingalpha.com/pr/17710468-kindred-biosciences-receives-fda-approval-zimeta-dipyrone-injection-control-pyrexia-horses\" target=\"_blank\">approved</a> Zimeta (dipyrone injection) for the control of pyrexia in horses.</li><li>The approval follows a clinical study in which the drug showed rapid and effective fever reduction in horses with naturally occurring fever.</li><li>KIN says Zimeta is the first and only FDA-approved medication for the control of pyrexia (fever) in horses.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521954\" data-linked=\"Kindred Bio wins FDA approval of Zimeta for control of equine pyrexia\" data-tweet=\"$KIN - Kindred Bio wins FDA approval of Zimeta for control of equine pyrexia https://seekingalpha.com/news/3521954-kindred-bio-wins-fda-approval-of-zimeta-for-control-of-equine-pyrexia?source=tweet\" data-url=\"https://seekingalpha.com/news/3521954-kindred-bio-wins-fda-approval-of-zimeta-for-control-of-equine-pyrexia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521952\" data-ts=\"1574723032\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAFE\" target=\"_blank\">SAFE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521952-safehold-to-join-s-and-p-smallcap-600\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Safehold to join S&amp;P SmallCap 600</a></h4><ul><li>Safehold (NYSE:<a href='https://seekingalpha.com/symbol/SAFE' title='Safehold Inc.'>SAFE</a>) <font color=\"green\">+6.2%</font> after-hours on news it <a href=\"https://us.spindices.com/indices/equity/sp-600\" target=\"_blank\">will replace</a> Oritani Financial (NASDAQ:<a href='https://seekingalpha.com/symbol/ORIT' title='Oritani Financial Corp.'>ORIT</a>) in the S&amp;P SmallCap 600, effective with the open of trading on Dec. 3.</li><li>Valley National Bancorp is acquiring Oritani in a deal expected to be completed soon pending final conditions.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521952\" data-linked=\"Safehold to join S&amp;P SmallCap 600\" data-tweet=\"$SAFE $ORIT - Safehold to join S&amp;P SmallCap 600 https://seekingalpha.com/news/3521952-safehold-to-join-s-and-p-smallcap-600?source=tweet\" data-url=\"https://seekingalpha.com/news/3521952-safehold-to-join-s-and-p-smallcap-600\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521949\" data-ts=\"1574722436\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTS\" target=\"_blank\">FTS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521949-fortis-announces-c-1_1b-in-concurrent-stock-offerings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fortis announces C$1.1B in concurrent stock offerings</a></h4><ul><li>Fortis (NYSE:<a href='https://seekingalpha.com/symbol/FTS' title='Fortis Inc.'>FTS</a>) <font color=\"red\">-1.9%</font> after-hours after unveiling plans for <a href=\"https://seekingalpha.com/pr/17710545-fortis-inc-announces-c-1_1-billion-offering-common-shares-comprised-c-600-million-bought-deal\" target=\"_blank\">C$1.1B in public offerings</a> of common shares, comprised of a C$600M bought deal financing and a concurrent C$500M offering to an institutional investor.</li><li>FTS says the underwriters will purchase on a bought deal basis and sell to the public ~11.5M common shares at C$52.15 each, with an option to purchase up to an additional ~1.72M shares.</li><li>Together with the bought deal, FTS says an unnamed U.S. institutional investor will purchase ~9.58M common shares at C$52.15/share.</li><li>FTS says the net proceeds will be used to fund its  capital plan and pay down debt, as well as for general corporate  purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521949\" data-linked=\"Fortis announces C$1.1B in concurrent stock offerings\" data-tweet=\"$FTS - Fortis announces C$1.1B in concurrent stock offerings https://seekingalpha.com/news/3521949-fortis-announces-c-1_1b-in-concurrent-stock-offerings?source=tweet\" data-url=\"https://seekingalpha.com/news/3521949-fortis-announces-c-1_1b-in-concurrent-stock-offerings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521946\" data-ts=\"1574721170\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521946-hpe-panw-ntnx-and-amba-among-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HPE, PANW, NTNX and AMBA among after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/CCXI' title='ChemoCentryx, Inc.'>CCXI</a> <font color=\"green\">+305.7%</font>. <a href='https://seekingalpha.com/symbol/IFRX' title='InflaRx N.V.'>IFRX</a> <font color=\"green\">+24.1%</font>. <a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix, Inc.'>NTNX</a> <font color=\"green\">+19.2%</font>. <a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella, Inc.'>AMBA</a> <font color=\"green\">+6.6%</font>. <a href='https://seekingalpha.com/symbol/ETRN' title='Equitrans Midstream Corporation'>ETRN</a> <font color=\"green\">+3.8%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a> <font color=\"red\">-8.9%</font>. <a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks, Inc.'>PANW</a> <font color=\"red\">-8.0%. </font><a href='https://seekingalpha.com/symbol/BECN' title='Beacon Roofing Supply, Inc.'>BECN</a> <font color=\"red\">-4.1%</font>. <a href='https://seekingalpha.com/symbol/SJT' title='San Juan Basin Royalty Trust'>SJT</a> <font color=\"red\">-3.8%</font>. <a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise Company'>HPE</a> <font color=\"red\">-3.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521946\" data-linked=\"HPE, PANW, NTNX and AMBA among after hour movers\" data-tweet=\"$CCXI $IFRX $NTNX - HPE, PANW, NTNX and AMBA among after hour movers https://seekingalpha.com/news/3521946-hpe-panw-ntnx-and-amba-among-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521946-hpe-panw-ntnx-and-amba-among-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521943\" data-ts=\"1574720417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACAD\" target=\"_blank\">ACAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521943-acadiaminus-2-after-mixed-pimavanserin-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ACADIA -2% after mixed pimavanserin results</a></h4><ul><li>ACADIA Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACAD' title='ACADIA Pharmaceuticals Inc.'>ACAD</a>) <font color=\"red\">slips 2% </font>after the <a href=\"https://seekingalpha.com/pr/17710466-acadia-pharmaceuticals-announces-positive-top-line-results-advance-trial-pimavanserin\" target=\"_blank\">results</a> from its ADVANCE study of pimavanserin as a treatment for negative symptoms of schizophrenia.</li><li>The study narrowly met its primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 compared to placebo. A greater improvement was seen in 53.8% of the 107 patients receiving the 34 mg dose.</li><li>Pimavanserin failed to meet the secondary endpoint of separating from placebo on the Personal and Social Performance scale.</li><li>The company plans to launch a second pivotal study with the 34 mg dose in H1 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521943\" data-linked=\"ACADIA -2% after mixed pimavanserin results\" data-tweet=\"$ACAD - ACADIA -2% after mixed pimavanserin results https://seekingalpha.com/news/3521943-acadiaminus-2-after-mixed-pimavanserin-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3521943-acadiaminus-2-after-mixed-pimavanserin-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521928\" data-ts=\"1574718922\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMBA\" target=\"_blank\">AMBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521928-ambarellaplus-8-after-beats-upside-revenue-view\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ambarella +8% after beats, upside revenue view</a></h4><ul><li>Ambarella (NASDAQ:<a href='https://seekingalpha.com/symbol/AMBA' title='Ambarella, Inc.'>AMBA</a>) <font color=\"green\">gains 8%</font> after <a href=\"https://seekingalpha.com/news/3521900-ambarella-eps-beats-0_11-beats-revenue\" target=\"_blank\">Q3 beats</a> with upside Q4 guidance, seeing $55-59M in revenue, 56.5-58.5% gross margin, and $29.5-31.5M in operating expenses.</li><li>The Q3 adjusted gross margin was 58.1% versus the 57.1% consensus and 60.9% Y/Y.</li><li>Operating expenses totaled $46.3M.</li><li>Earnings call started at 4:30 PM with a webcast and replay available <a href=\"https://www.globenewswire.com/Tracker?data=uaD_2l1olFPWp__M8O2fwyUIQr7_BqZISDs9qLpQajCEKt7j1-INIhXhCUg41uGaFlnd85NPBqoGTTjbgqZrN2LnEwnNUytaeWntl_MLl3A=\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17710475-ambarella-inc-announces-third-quarter-fiscal-year-2020-financial-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521928\" data-linked=\"Ambarella +8% after beats, upside revenue view\" data-tweet=\"$AMBA - Ambarella +8% after beats, upside revenue view https://seekingalpha.com/news/3521928-ambarellaplus-8-after-beats-upside-revenue-view?source=tweet\" data-url=\"https://seekingalpha.com/news/3521928-ambarellaplus-8-after-beats-upside-revenue-view\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521927\" data-ts=\"1574718792\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XFOR\" target=\"_blank\">XFOR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521927-x4-pharma-launches-public-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">X4 Pharma launches public offering</a></h4><ul><li>X4 Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/XFOR' title='X4 Pharmaceuticals, Inc.'>XFOR</a>) <font color=\"red\">-9.4%</font> after-hours on news it commenced an underwritten <a href=\"https://seekingalpha.com/pr/17710448-x4-pharmaceuticals-announces-proposed-public-offering\" target=\"_blank\">public offering</a> of common shares and Class B warrants.</li><li>The planned size and terms of the offering are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521927\" data-linked=\"X4 Pharma launches public offering\" data-tweet=\"$XFOR - X4 Pharma launches public offering https://seekingalpha.com/news/3521927-x4-pharma-launches-public-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3521927-x4-pharma-launches-public-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521924\" data-ts=\"1574718301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPE\" target=\"_blank\">HPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521924-hpeminus-3_4-after-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HPE -3.4% after revenue miss</a></h4><ul><li>Hewlett Packard Enterprise (NYSE:<a href='https://seekingalpha.com/symbol/HPE' title='Hewlett Packard Enterprise Company'>HPE</a>) <font color=\"red\">-3.4%</font> reports mixed <a href=\"https://seekingalpha.com/news/3521899-hewlett-packard-enterprise-eps-beats-0_03-misses-revenue\" target=\"_blank\">Q4 results</a> that beat earnings estimates but missed on revenue.</li><li>HPE's outlook includes inline EPS for Q1 and FY20, seeing $0.42-0.46 and $1.78-1.94, respectively.</li><li>In Q4, Hybrid IT revenue fell short of estimates with $5.67B versus $5.74B with the most notable weakness in Storage.</li><li>Intelligent Edge also fell short with $723M in overall sales (consensus: $767.5M) and Aruba product reporting $620M versus the $668M consensus.</li><li>Cash flow from operations totaled $1.43B.</li><li>Earnings call starts at 5 PM ET with a webcast <a href=\"https://investors.hpe.com/#q4-fiscal-year-2019-hewlett-packard-enterprise-earnings-conference-call\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17710479-hpe-reports-fiscal-2019-fourth-quarter-full-year-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521924\" data-linked=\"HPE -3.4% after revenue miss\" data-tweet=\"$HPE - HPE -3.4% after revenue miss https://seekingalpha.com/news/3521924-hpeminus-3_4-after-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3521924-hpeminus-3_4-after-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521923\" data-ts=\"1574718141\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCXI\" target=\"_blank\">CCXI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521923-chemocentryx-triples-after-positive-test-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ChemoCentryx more than triples after positive test results</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17710485-chemocentryx-vfmcrp-announce-positive-topline-data-pivotal-phase-iii-advocate-trial\" target=\"_blank\">The company announces</a> positive topline data from its pivotal Phase III ADVOCATE trial for avacopan.</li><li>The test achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care &#40;SOC&#41; at 52 weeks.</li><li>Other notes: Significantly reduced glucocorticoid toxicity, significantly improved kidney function compared to glucocorticoid-containing SOC, improved health-related quality of life measures compared to SOC</li><li>A <a href=\"https://www.chemocentryx.com/\" target=\"_blank\">conference call</a> is just underway.</li><li><a href='https://seekingalpha.com/symbol/CCXI' title='ChemoCentryx, Inc.'>CCXI</a> <font color=\"green\">+265.4%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3521923\" data-linked=\"ChemoCentryx more than triples after positive test results\" data-tweet=\"$CCXI - ChemoCentryx more than triples after positive test results https://seekingalpha.com/news/3521923-chemocentryx-triples-after-positive-test-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3521923-chemocentryx-triples-after-positive-test-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521919\" data-ts=\"1574717657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PANW\" target=\"_blank\">PANW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521919-palo-altominus-7-after-downside-fy-eps-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Palo Alto -7% after downside FY EPS outlook</a></h4><ul><li>Palo Alto Networks (NYSE:<a href='https://seekingalpha.com/symbol/PANW' title='Palo Alto Networks, Inc.'>PANW</a>) <font color=\"red\">-7.2%</font> <a href=\"https://seekingalpha.com/news/3521909-palo-alto-networks-eps-beats-0_02-beats-revenue\" target=\"_blank\">beats</a> the Street's Q1 estimates with revenue growth of 18% Y/Y. The company forecasts inline Q2 revenue of $838M-848M versus the $845.9M consensus and EPS of $1.11-1.13.</li><li>The FY outlook has inline revenue of $3.44B-3.48B and downside earnings of $4.90-5.00 (consensus: $5.07).</li><li>Q1 billings revenue dropped 4% Y/Y to $231.2M. Subscription and support revenue grew 30% to $540.7M.</li><li>Billings were up 18% Y/Y to $897.4M.</li><li>Earnings call starts at 4:30 PM ET with a webcast<a href=\"https://c212.net/c/link/?t=0&amp;l=en&amp;o=2653162-1&amp;h=2754277701&amp;u=https%3A%2F%2Finvestors.paloaltonetworks.com%2F&amp;a=investors.paloaltonetworks.com\" target=\"_blank\"> here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17710516-palo-alto-networks-reports-fiscal-first-quarter-2020-financial-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521919\" data-linked=\"Palo Alto -7% after downside FY EPS outlook\" data-tweet=\"$PANW - Palo Alto -7% after downside FY EPS outlook https://seekingalpha.com/news/3521919-palo-altominus-7-after-downside-fy-eps-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3521919-palo-altominus-7-after-downside-fy-eps-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:34 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521917\" data-ts=\"1574717374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVH\" target=\"_blank\">PVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521917-pvh-cautious-on-holiday-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PVH cautious on holiday quarter</a></h4><ul> <li>PVH (NYSE:<a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a>) tracks slightly higher after topping <a href=\"https://seekingalpha.com/pr/17710517-pvh-corp-reports-2019-third-quarter-results-guidance-raises-full-year-outlook\" target=\"_blank\">Q3</a> estimates, but issuing cautious guidance.</li> <li>The company sees Q4 revenue of ~$2.53B (level with consensus) and EPS of $1.77 to $1.79 vs. $1.82 consensus. For the full year, PVH anticipates revenue of ~$9.75B vs. $9.79B consensus and EPS of $9.43 to $9.45 vs. $9.39 consensus.</li> <li>PVH says it's taking a prudent approach to planning its business for the holiday quarter. \"We believe the current holiday season will be very competitive and highly promotional, and expect that the macroeconomic and geopolitical volatility we are experiencing globally will remain a headwind,\" warns PVH.</li><li>PVH <font color=\"green\">+0.44%</font> AH.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3521911-phillips-van-heusen-eps-beats-0_11-beats-revenue\" target=\"_blank\">Phillips-Van Heusen EPS beats by $0.11, beats on revenue</a> (Nov. 25)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521917\" data-linked=\"PVH cautious on holiday quarter\" data-tweet=\"$PVH - PVH cautious on holiday quarter https://seekingalpha.com/news/3521917-pvh-cautious-on-holiday-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3521917-pvh-cautious-on-holiday-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521915\" data-ts=\"1574716823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521915-nutanixplus-15_8-after-upside-q1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutanix +15.8% after upside Q1</a></h4><ul><li>Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix, Inc.'>NTNX</a>) <font color=\"green\">gains 15.8%</font> after <a href=\"https://seekingalpha.com/news/3521897-nutanix-eps-beats-0_04-beats-revenue\" target=\"_blank\">Q1 beats</a> with in-line Q2 earnings guidance.</li><li>Q1 adjusted gross margin matched consensus at 80.1%, compared to 78.6% in last year's quarter.</li><li>Billings totaled $380M, down from last year's $383.6M due to the ongoing transition to subscription and \"significant reduction\" of hardware billings.</li><li>Software and support revenue was up 9% Y/Y to $305M.</li><li>Q2 outlook has software and support billings of $410M-$420M, software and support revenue of $330M-$335M, gross margin of 80%, and a net loss per share of ~$0.70, in line with the analyst consensus estimate.</li><li>The FY20 view has software and support billings of $1.65B-$1.75B and revenue of $1.3B-$1.4B with gross margin of 80%.</li><li>Earnings call starts at 4:30 PM ET with a webcast <a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.nutanix.com%2F&amp;esheet=52134765&amp;newsitemid=20191125005740&amp;lan=en-US&amp;anchor=ir.nutanix.com&amp;index=13&amp;md5=3d52b42a68a922b19d95a07fb4194666\" target=\"_blank\">here</a>.</li><li><a href=\"https://seekingalpha.com/pr/17710462-nutanix-reports-first-quarter-fiscal-2020-financial-results\" target=\"_blank\">Press release</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521915\" data-linked=\"Nutanix +15.8% after upside Q1\" data-tweet=\"$NTNX - Nutanix +15.8% after upside Q1 https://seekingalpha.com/news/3521915-nutanixplus-15_8-after-upside-q1?source=tweet\" data-url=\"https://seekingalpha.com/news/3521915-nutanixplus-15_8-after-upside-q1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521911\" data-ts=\"1574716653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PVH\" target=\"_blank\">PVH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521911-phillips-van-heusen-eps-beats-0_11-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Phillips-Van Heusen EPS beats by $0.11, beats on revenue</a></h4><ul><li>Phillips-Van Heusen (NYSE:<a href='https://seekingalpha.com/symbol/PVH' title='PVH Corp.'>PVH</a>): Q3 Non-GAAP EPS of $3.10 <font color=\"green\">beats by $0.11</font>; GAAP EPS of $2.82 <font color=\"green\">beats by $0.08</font>.</li><li>Revenue of $2.59B (+2.8% Y/Y) <font color=\"green\">beats by $50M</font>.</li><li>Shares <font color=\"green\">+1.99%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17710517-pvh-corp-reports-2019-third-quarter-results-guidance-raises-full-year-outlook\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3521911\" data-linked=\"Phillips-Van Heusen EPS beats by $0.11, beats on revenue\" data-tweet=\"$PVH - Phillips-Van Heusen EPS beats by $0.11, beats on revenue https://seekingalpha.com/news/3521911-phillips-van-heusen-eps-beats-0_11-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3521911-phillips-van-heusen-eps-beats-0_11-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521910\" data-ts=\"1574716640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CAL\" target=\"_blank\">CAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521910-caleresminus-2-after-light-profit-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Caleres -2% after light profit outlook</a></h4><ul> <li>Caleres (NYSE:<a href='https://seekingalpha.com/symbol/CAL' title='Caleres, Inc.'>CAL</a>) reports Famous Footwear same-store sales were up 2.5% in <a href=\"https://seekingalpha.com/pr/17710494-caleres-reports-third-quarter-2019-results\" target=\"_blank\">Q3</a>.</li> <li>The retailer says its gross margin was 40.4% of sales during the quarter vs. 40.3% a year ago and operating margin was 5.6% of sales vs. 6.0% a year ago.</li> <li>Looking ahead, Caleres narrows full-year profit guidance to a range of $2.35 to $2.40 vs. $2.35 to $2.45 prior view and $2.42 consensus.</li> <li>Shares of Caleres are <font color=\"red\">down 1.98%</font> AH to $21.79.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3521905-caleres-eps-misses-0_05-misses-revenue\" target=\"_blank\">Caleres EPS misses by $0.05, misses on revenue</a> (Nov. 25)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521910\" data-linked=\"Caleres -2% after light profit outlook\" data-tweet=\"$CAL - Caleres -2% after light profit outlook https://seekingalpha.com/news/3521910-caleresminus-2-after-light-profit-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3521910-caleresminus-2-after-light-profit-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521904\" data-ts=\"1574716285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CVS\" target=\"_blank\">CVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521904-starboard-value-takes-stake-in-cvs-dow-jones\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Starboard Value takes stake in CVS - Dow Jones</a></h4><ul><li>The stake is relatively small and talks with management are amicable, according to the report, but activist investor Starboard Value owns shares of CVS (NYSE:<a href='https://seekingalpha.com/symbol/CVS' title='CVS Health Corporation'>CVS</a>).</li><li>Shares jumped more than 2% as the headline hit, they're now <font color=\"green\">up 1.9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521904\" data-linked=\"Starboard Value takes stake in CVS - Dow Jones\" data-tweet=\"$CVS - Starboard Value takes stake in CVS - Dow Jones https://seekingalpha.com/news/3521904-starboard-value-takes-stake-in-cvs-dow-jones?source=tweet\" data-url=\"https://seekingalpha.com/news/3521904-starboard-value-takes-stake-in-cvs-dow-jones\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:11 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521897\" data-ts=\"1574715802\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTNX\" target=\"_blank\">NTNX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521897-nutanix-eps-beats-0_04-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutanix EPS beats by $0.04, beats on revenue</a></h4><ul><li>Nutanix (NASDAQ:<a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix, Inc.'>NTNX</a>): Q1 Non-GAAP EPS of -$0.71 <font color=\"green\">beats by $0.04</font>; GAAP EPS of -$1.21 <font color=\"red\">misses by $0.13</font>.</li><li>Revenue of $314.8M (+0.5% Y/Y) <font color=\"green\">beats by $8.38M</font>.</li><li>Shares <font color=\"green\">+3.5%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17710462-nutanix-reports-first-quarter-fiscal-2020-financial-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3521897\" data-linked=\"Nutanix EPS beats by $0.04, beats on revenue\" data-tweet=\"$NTNX - Nutanix EPS beats by $0.04, beats on revenue https://seekingalpha.com/news/3521897-nutanix-eps-beats-0_04-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3521897-nutanix-eps-beats-0_04-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>57&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521895\" data-ts=\"1574715678\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERIC\" target=\"_blank\">ERIC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521895-ericsson-investing-238m-in-brazil-5g-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ericsson investing $238M in Brazil 5G line</a></h4><ul><li>Ericsson (<a href='https://seekingalpha.com/symbol/ERIC' title='Telefonaktiebolaget LM Ericsson &#40;publ&#41;'>ERIC</a> <font color='green'>+1.1%</font>) <a href=\"https://www.reuters.com/article/us-ericsson-brazil/ericsson-to-invest-over-230-million-in-brazil-5g-assembly-line-idUSKBN1XZ2D5\" target=\"_blank\">will invest</a> $238.2M in Brazil to add a new 5G assembly line to supply its Latin American operations.</li><li>Nokia and Huawei also have factories in Sao Paulo and want to lead 5G deployment in Brazil.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521895\" data-linked=\"Ericsson investing $238M in Brazil 5G line\" data-tweet=\"$ERIC - Ericsson investing $238M in Brazil 5G line https://seekingalpha.com/news/3521895-ericsson-investing-238m-in-brazil-5g-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3521895-ericsson-investing-238m-in-brazil-5g-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521893\" data-ts=\"1574714900\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521893-baird-sees-atvi-ea-holiday-hits\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird sees ATVI, EA as holiday hits</a></h4><ul><li>Baird's pre-holiday survey shows Activision's (<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc.'>ATVI</a> <font color='green'>+1.1%</font>) <em>Call of Duty Modern Warfare</em> as the most anticipated game of the season.</li><li>EA's (<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a> <font color='green'>+0.4%</font>) <em>Star Wars Jedi: Fallen Order </em>\"surprised to the upside as a close second favorite.\"</li><li>The survey results show \"purchase intent among consumers stronger this year despite a less robust release slate vs. last year.\"</li><li>Baird maintains an Outperform rating on the gaming companies. <a href=\"https://seekingalpha.com/symbol/EA/ratings/sell-side-ratings\" target=\"_blank\">EA</a> and <a href=\"https://seekingalpha.com/symbol/ATVI/ratings/sell-side-ratings?s=atvi\" target=\"_blank\">ATVI</a> have Bullish average Sell Side ratings.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521893\" data-linked=\"Baird sees ATVI, EA as holiday hits\" data-tweet=\"$ATVI $EA - Baird sees ATVI, EA as holiday hits https://seekingalpha.com/news/3521893-baird-sees-atvi-ea-holiday-hits?source=tweet\" data-url=\"https://seekingalpha.com/news/3521893-baird-sees-atvi-ea-holiday-hits\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521957\" data-ts=\"1574714140\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOE\" target=\"_blank\">FOE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521957-ferro-exploring-potential-sale-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ferro exploring potential sale - Bloomberg</a></h4><ul><li>Ferro (<a href='https://seekingalpha.com/symbol/FOE' title='Ferro Corporation'>FOE</a> <font color='green'>+12.9%</font>) shares spike higher following a Bloomberg report that the chemicals company is exploring strategic options including a <a href=\"https://www.bnnbloomberg.ca/chemicals-maker-ferro-to-explore-potential-sale-1.1353291\" target=\"_blank\">possible sale</a>.</li><li>Ferro is exploring a sale as tepid growth and volatile  commodity prices have convinced other industry players to consolidate; Axalta Coating Systems (<a href='https://seekingalpha.com/symbol/AXTA' title='Axalta Coating Systems Ltd.'>AXTA</a> <font color='green'>+1.1%</font>) is said to be exploring a sale, and Celanese (<a href='https://seekingalpha.com/symbol/CE' title='Celanese Corporation'>CE</a> <font color='green'>+1.3%</font>) is undertaking a strategic review that could include a  breakup.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521957\" data-linked=\"Ferro exploring potential sale - Bloomberg\" data-tweet=\"$FOE $AXTA $CE - Ferro exploring potential sale - Bloomberg https://seekingalpha.com/news/3521957-ferro-exploring-potential-sale-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3521957-ferro-exploring-potential-sale-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521892\" data-ts=\"1574713441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLUG\" target=\"_blank\">PLUG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521892-plug-power-in-rally-mode-b-riley-analyst-lifts-price-target-to-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plug Power in rally mode as B. Riley analyst lifts price target to $6</a></h4><ul><li>Plug Power (<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power Inc.'>PLUG</a> <font color='green'>+10.4%</font>) pushes to multi-year highs as B. Riley FBR <a href=\"https://thefly.com/thestreet/realmoney/index.php/PLUGid2998821/PLUG-Plug-Power-price-target-raised-to--from--at-B-Riley-FBR\" target=\"_blank\">reiterates its Buy rating</a> and raises its price target to $6/share from $3.50, equaling ~6x EV/revenues.</li><li>B. Riley analyst Christopher Van Horn thinks the multiple is appropriate, given PLUG's implied 35% five-year compound annual growth rate from his 2019 revenue estimates, and nearly  90% four-year CAGR from his 2020 adjusted EBITDA estimate.</li><li>PLUG's long-term revenue target of $1B over the next five years, with $200M in adjusted EBITDA, \"seems highly probable,\" given recent industry- and company-specific fundamentals, says Van Horn, who believes the stock and PLUG's fuel cell technology seem to be at an inflection point and that the company is better positioned in its core material  handling business than ever before.</li><li>PLUG's average <a href=\"https://seekingalpha.com/symbol/PLUG/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> is Very Bullish, but both its <a href=\"https://seekingalpha.com/symbol/PLUG/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> and <a href=\"https://seekingalpha.com/symbol/PLUG/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> are Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521892\" data-linked=\"Plug Power in rally mode as B. Riley analyst lifts price target to $6\" data-tweet=\"$PLUG - Plug Power in rally mode as B. Riley analyst lifts price target to $6 https://seekingalpha.com/news/3521892-plug-power-in-rally-mode-b-riley-analyst-lifts-price-target-to-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3521892-plug-power-in-rally-mode-b-riley-analyst-lifts-price-target-to-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521891\" data-ts=\"1574713310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521891-global-blood-therapeuticsplus-7-on-report-of-fda-win\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Global Blood Therapeutics +7% on report of FDA win</a></h4><ul> <li>Shares of Global Blood Therapeutics (<a href='https://seekingalpha.com/symbol/GBT' title='Global Blood Therapeutics, Inc.'>GBT</a> <font color=\"green\">+6.7%</font>) have been halted with news pending.</li> <li>Bloomberg reports the company landed a key approval from the FDA for Oxbryta (voxelotor) as a treatment for sickle cell disease, although there is no official word yet from the company.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521891\" data-linked=\"Global Blood Therapeutics +7% on report of FDA win\" data-tweet=\"$GBT - Global Blood Therapeutics +7% on report of FDA win https://seekingalpha.com/news/3521891-global-blood-therapeuticsplus-7-on-report-of-fda-win?source=tweet\" data-url=\"https://seekingalpha.com/news/3521891-global-blood-therapeuticsplus-7-on-report-of-fda-win\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521888\" data-ts=\"1574712402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BYND\" target=\"_blank\">BYND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521888-investors-size-up-beyond-meat-and-impossible-foods\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors size up Beyond Meat and Impossible Foods</a></h4><ul> <li>Beyond Meat (<a href='https://seekingalpha.com/symbol/BYND' title='Beyond Meat, Inc.'>BYND</a> <font color='green'>+1.3%</font>) turns higher after sitting in negative territory for much of the session.</li> <li>The jump is being attributed to word that Impossible Foods (IMPSBL) is in talks with investors about a new funding round that could double the alternative protein company's valuation from the last funding round.</li><li>Beyond Meat still trades at 3X the level where the company's IPO was priced. The strong rally in BYND has pushed most of the sell-side community to the sidelines.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521888\" data-linked=\"Investors size up Beyond Meat and Impossible Foods\" data-tweet=\"$BYND - Investors size up Beyond Meat and Impossible Foods https://seekingalpha.com/news/3521888-investors-size-up-beyond-meat-and-impossible-foods?source=tweet\" data-url=\"https://seekingalpha.com/news/3521888-investors-size-up-beyond-meat-and-impossible-foods\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521886\" data-ts=\"1574712052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521886-globalscape-and-plug-power-among-tech-movers-ameri-holdings-and-the9-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GlobalSCAPE and Plug Power among Tech movers; AMERI Holdings and The9 among losers</a></h4><ul><li><b>Gainers: </b>GlobalSCAPE (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSB' title='GlobalSCAPE, Inc.'>GSB</a>) <font color=\"green\">+15%</font>. Plug Power (NASDAQ:<a href='https://seekingalpha.com/symbol/PLUG' title='Plug Power Inc.'>PLUG</a>) <font color=\"green\">+11%</font>. Applied DNA Sciences APDN <font color=\"green\">+10%</font>. Zscaler (NASDAQ:<a href='https://seekingalpha.com/symbol/ZS' title='Zscaler, Inc.'>ZS</a>) <font color=\"green\">+9%</font>. Ooma (NYSE:<a href='https://seekingalpha.com/symbol/OOMA' title='Ooma, Inc.'>OOMA</a>) <font color=\"green\">+8%</font>.</li><li><b>Losers: </b>AMERI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/AMRH' title='AMERI Holdings, Inc.'>AMRH</a>) <font color=\"red\">-18%</font>. The9 (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-15%</font>. SPI Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/SPI' title='SPI Energy Co., Ltd.'>SPI</a>) <font color=\"red\">-11%</font>. Aurora Mobile (NASDAQ:<a href='https://seekingalpha.com/symbol/JG' title='Aurora Mobile Limited'>JG</a>) <font color=\"red\">-10%</font>. Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"red\">-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521886\" data-linked=\"GlobalSCAPE and Plug Power among Tech movers; AMERI Holdings and The9 among losers\" data-tweet=\"$GSB $PLUG $ZS - GlobalSCAPE and Plug Power among Tech movers; AMERI Holdings and The9 among losers https://seekingalpha.com/news/3521886-globalscape-and-plug-power-among-tech-movers-ameri-holdings-and-the9-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521886-globalscape-and-plug-power-among-tech-movers-ameri-holdings-and-the9-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521885\" data-ts=\"1574711888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBBY\" target=\"_blank\">BBBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521885-bed-bath-beyondplus-8-on-baml-confidence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bed Bath &amp; Beyond +8% on BAML confidence</a></h4><ul> <li>Bed Bath &amp; Beyond (NASDAQ:<a href='https://seekingalpha.com/symbol/BBBY' title='Bed Bath & Beyond Inc.'>BBBY</a>) rallies after positive comments from Bank of America Merrill Lynch analyst Curtis Nagle.</li> <li>\"We continue to see a substantial opportunity for higher earnings and share price performance for BBBY through: 1) divesting non-core and unprofitable assets; 2) cost reductions and store rationalization after years of highly inefficient spending; 3) the sale of real estate and secondary concepts; and 4) significant improvements to product merchandising, sourcing and in-store and online operations.\"</li> <li>The firm keeps a Buy rating on BBBY and price objective of $20 (+50% upside potential).</li> <li>Shares of Bed Bath &amp; Beyond are <font color=\"green\">up 8.26%</font> to reverse last week's stumble.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521885\" data-linked=\"Bed Bath &amp; Beyond +8% on BAML confidence\" data-tweet=\"$BBBY - Bed Bath &amp; Beyond +8% on BAML confidence https://seekingalpha.com/news/3521885-bed-bath-beyondplus-8-on-baml-confidence?source=tweet\" data-url=\"https://seekingalpha.com/news/3521885-bed-bath-beyondplus-8-on-baml-confidence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521884\" data-ts=\"1574710370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JAN\" target=\"_blank\">JAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521884-janone-acquires-license-for-artery-disease-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">JanOne acquires license for artery disease treatment</a></h4><ul><li>JanOne (<a href='https://seekingalpha.com/symbol/JAN' title='JanOne Inc.'>JAN</a> <font color=\"green\">+79.2%</font>) spikes after announcing a <a href=\"https://seekingalpha.com/pr/17709957-janone-acquires-worldwide-exclusive-license-promising-treatment-peripheral-arterial-disease\" target=\"_blank\">licensing agreement</a> for its TV1001SR treatment for peripheral artery disease.</li><li>JAN says the deal with LSU Health Shreveport, UAB Research Foundation and TheraVasc provides a worldwide, exclusive license for TV1001SR along with a portfolio of 30 patents and other intellectual property relating to the sustained release of sodium nitrite.</li><li>The company thinks TV1001SR will be a groundbreaking treatment for  patients with PAD, for which there is no known efficacious single-drug treatment and affects more than 200M  people worldwide and 8.5M in the U.S.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521884\" data-linked=\"JanOne acquires license for artery disease treatment\" data-tweet=\"$JAN - JanOne acquires license for artery disease treatment https://seekingalpha.com/news/3521884-janone-acquires-license-for-artery-disease-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3521884-janone-acquires-license-for-artery-disease-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521879\" data-ts=\"1574708836\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TIVO\" target=\"_blank\">TIVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521879-tivo-completes-refinancing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TiVo completes refinancing</a></h4><ul><li>TiVo (<a href='https://seekingalpha.com/symbol/TIVO' title='TiVo Corporation'>TIVO</a> <font color=\"green\">+5.8%</font>) <a href=\"https://seekingalpha.com/pr/17710143-tivo-corporation-announces-completion-refinancing\" target=\"_blank\">entered</a> into a new $715M Term Loan Credit Agreement with HPS Investment Partners as administrative and collateral agent, plus a $60M Revolving Loan Credit Agreement with Morgan Stanley Senior Funding and Wells Fargo Bank, National Association.</li><li>TiVo used the proceeds of the new term loan to repay loans under its existing term loan B facility and add cash to the balance sheet in anticipation of its Product business spin-off</li></ul><div class=\"tiny-share-widget\" data-id=\"3521879\" data-linked=\"TiVo completes refinancing\" data-tweet=\"$TIVO - TiVo completes refinancing https://seekingalpha.com/news/3521879-tivo-completes-refinancing?source=tweet\" data-url=\"https://seekingalpha.com/news/3521879-tivo-completes-refinancing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521878\" data-ts=\"1574708645\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521878-highpoint-resources-and-ferro-among-energy-materials-gainers-kirkland-lake-gold-and-camber\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HighPoint Resources and Ferro among Energy/Materials gainers; Kirkland Lake Gold and Camber Energy among losers</a></h4><ul><li><b>Gainers: </b>HighPoint Resources (NYSE:<a href='https://seekingalpha.com/symbol/HPR' title='HighPoint Resources Corporation'>HPR</a>) <font color=\"green\">+16%</font>. Ferro (NYSE:<a href='https://seekingalpha.com/symbol/FOE' title='Ferro Corporation'>FOE</a>) <font color=\"green\">+15%</font>. Hallador Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/HNRG' title='Hallador Energy Company'>HNRG</a>) <font color=\"green\">+12%</font>. Forum Energy Technologies (NYSE:<a href='https://seekingalpha.com/symbol/FET' title='Forum Energy Technologies, Inc.'>FET</a>) <font color=\"green\">+12%</font>. Permianville Royalty Trust (NYSE:<a href='https://seekingalpha.com/symbol/PVL' title='Permianville Royalty Trust'>PVL</a>) <font color=\"green\">+12%</font>.</li><li><b>Losers: </b>Kirkland Lake Gold (NYSE:<a href='https://seekingalpha.com/symbol/KL' title='Kirkland Lake Gold Ltd.'>KL</a>) <font color=\"red\">-16%</font>. Camber Energy (NYSEMKT:<a href='https://seekingalpha.com/symbol/CEI' title='Camber Energy, Inc.'>CEI</a>) <font color=\"red\">-11%</font>. Summit Midstream Partners (NYSE:<a href='https://seekingalpha.com/symbol/SMLP' title='Summit Midstream Partners, LP'>SMLP</a>) <font color=\"red\">-8%</font>. Lightbridge (NASDAQ:<a href='https://seekingalpha.com/symbol/LTBR' title='Lightbridge Corporation'>LTBR</a>) <font color=\"red\">-6%</font>. Endeavour Silver (NYSE:<a href='https://seekingalpha.com/symbol/EXK' title='Endeavour Silver Corp.'>EXK</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521878\" data-linked=\"HighPoint Resources and Ferro among Energy/Materials gainers; Kirkland Lake Gold and Camber Energy among losers\" data-tweet=\"$HPR $FOE $HNRG - HighPoint Resources and Ferro among Energy/Materials gainers; Kirkland Lake Gold and Camber Energy among losers https://seekingalpha.com/news/3521878-highpoint-resources-and-ferro-among-energy-materials-gainers-kirkland-lake-gold-and-camber?source=tweet\" data-url=\"https://seekingalpha.com/news/3521878-highpoint-resources-and-ferro-among-energy-materials-gainers-kirkland-lake-gold-and-camber\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521877\" data-ts=\"1574708576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BURL\" target=\"_blank\">BURL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521877-positive-vibes-on-burlington-stores-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Positive vibes on Burlington Stores ahead of earnings</a></h4><ul> <li>Burlington Stores (<a href='https://seekingalpha.com/symbol/BURL' title='Burlington Stores, Inc.'>BURL</a> <font color='green'>+1.3%</font>) is called a compelling <a href=\"https://www.thestreet.com/opinion/burlington-stores-third-quarter-looks-promising-15177897\" target=\"_blank\">buy</a> at current levels by TheStreet just a day ahead of the retailer's earnings report.</li> <li>\"The company is a rare case of high growth in the industry, and the stock's forward P/E of 25x seems at least consistent with a story of rapidly-increasing sales and earnings,\" reasons Daniel Martin.</li> <li>\"In addition, shares of off-price retailers will probably fare better than most other names in the market during periods of distress and macroeconomic softness, which is a great diversification feature of a stock like Burlington Stores,\" he adds.</li><li>Burlington is also popular on Wall Street, with <a href=\"https://seekingalpha.com/symbol/BURL/ratings/sell-side-ratings\" target=\"_blank\">16</a> of 24 firms covering the stock having a Buy-equivalent rating on the books.</li> <li>Shares of Burlington are up 28% YTD.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521877\" data-linked=\"Positive vibes on Burlington Stores ahead of earnings\" data-tweet=\"$BURL - Positive vibes on Burlington Stores ahead of earnings https://seekingalpha.com/news/3521877-positive-vibes-on-burlington-stores-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3521877-positive-vibes-on-burlington-stores-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521963\" data-ts=\"1574708254\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CF\" target=\"_blank\">CF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521963-cf-industries-nutrien-bumped-to-buy-baml\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CF Industries, Nutrien bumped to Buy at BAML</a></h4><ul><li>Fertilizer names CF Industries (<a href='https://seekingalpha.com/symbol/CF' title='CF Industries Holdings, Inc.'>CF</a> <font color='green'>+3%</font>) and Nutrien (<a href='https://seekingalpha.com/symbol/NTR' title='Nutrien Ltd.'>NTR</a> <font color='green'>+1.8%</font>) move higher after BofA Merrill Lynch <a href=\"https://thefly.com/thestreet/realmoney/index.php/CF;NTRid2998644/CF;NTR-BofA-upgrades-CF-Industries-Nutrien-to-Buy-with-nitrogen-seen-nearing-trough\" target=\"_blank\">upgrades both to Buy</a> from Neutral, with respective stock price targets of $56 and $54, as the firm foresees a price  inflection by spring in all three major nutrients after a year of lower fertilizer prices.</li><li>BAML analyst Steve Byrne believes strong demand in North America, Brazil and India should facilitate quick drawdowns and increased purchasing despite high phosphate and potash inventories, while limited capacity expansions and lower global exports also tighten the market.</li><li>CF's average <a href=\"https://seekingalpha.com/symbol/CF/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/CF/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> are both Bullish, while its <a href=\"https://seekingalpha.com/symbol/CF/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li><li>Also, NTR's average <a href=\"https://seekingalpha.com/symbol/NTR/ratings/sell-side-ratings\" target=\"_blank\">Sell Side Rating</a> and <a href=\"https://seekingalpha.com/symbol/NTR/ratings/author-ratings#filter=all\" target=\"_blank\">Seeking Alpha Authors' Rating</a> are Bullish, and its <a href=\"https://seekingalpha.com/symbol/NTR/ratings/quant-ratings\" target=\"_blank\">Quant Rating</a> is Neutral.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521963\" data-linked=\"CF Industries, Nutrien bumped to Buy at BAML\" data-tweet=\"$CF $NTR - CF Industries, Nutrien bumped to Buy at BAML https://seekingalpha.com/news/3521963-cf-industries-nutrien-bumped-to-buy-baml?source=tweet\" data-url=\"https://seekingalpha.com/news/3521963-cf-industries-nutrien-bumped-to-buy-baml\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521962\" data-ts=\"1574707444\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALNY\" target=\"_blank\">ALNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521962-novartis-deal-for-mdco-good-news-for-alnylam-arrowhead-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Novartis deal for MDCO good news for Alnylam, Arrowhead, analyst says</a></h4><ul><li>Alnylam Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ALNY' title='Alnylam Pharmaceuticals, Inc.'>ALNY</a> <font color='green'>+5.2%</font>) and Arrowhead Pharma (<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals, Inc.'>ARWR</a> <font color='green'>+15.8%</font>) are sharply higher, as Novartis' (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+0.9%</font>) <a href=\"https://seekingalpha.com/news/3521670-novartis-inks-9_7b-deal-medicines-co\" target=\"_blank\">$9.7B deal</a> for The Medicines Co. (<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a> <font color='green'>+22.2%</font>) is seen as <a href=\"https://www.barrons.com/articles/novartis-deal-medicines-company-alnylam-arrowhead-pharmaceuticals-51574695512\" target=\"_blank\">good news</a> for the two companies which are developing the same technology, says Jefferies analyst Maury Raycroft.</li><li>MDCO is developing a cholesterol drug called inclisiran, a small interfering RNA therapy, and ALNY - which co-developed inclisiran - and ARWR also are working on RNAi drugs, and now, \"with safety [and] proof-of-concept demonstrated across multiple therapeutic areas... we expect the platform potential to pique more interest,\" Raycroft writes.</li><li>ALNY also sells Onpattro, an RNAi drug that treats a genetic condition called hATTR amyloidosis.</li><li>\"Safety was an overhang for the space for years, but biotechs have identified problem areas and made adjustments,\" Raycroft says.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521962\" data-linked=\"Novartis deal for MDCO good news for Alnylam, Arrowhead, analyst says\" data-tweet=\"$ALNY $ARWR $NVS - Novartis deal for MDCO good news for Alnylam, Arrowhead, analyst says https://seekingalpha.com/news/3521962-novartis-deal-for-mdco-good-news-for-alnylam-arrowhead-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3521962-novartis-deal-for-mdco-good-news-for-alnylam-arrowhead-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521875\" data-ts=\"1574707005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521875-morgan-stanley-dials-up-conviction-on-mondelez-international\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Morgan Stanley dials up the conviction on Mondelez International</a></h4><ul> <li>Morgan Stanley expects accelerating topline growth out of Mondelez International (<a href='https://seekingalpha.com/symbol/MDLZ' title='Mondelez International, Inc.'>MDLZ</a> <font color=\"green\">+0.2%</font>) out of coming back from a meeting with management.</li>  <li>\"Overall, we thought management's tone in the meetings was positive and confident. We came away with increased conviction that MDLZ's strategic changes are resulting in a sustained improved topline growth outlook, driven by both rebounding category growth and MDLZ market share trends, and that recent gross margin pressure is likely to dissipate in 2020 as Brazil supply chain hiccups are alleviated. We reiterate our OW on MDLZ as we believe positive strategic changes are resulting in an improved topline growth outlook and expect multiple expansion more towards multinational CPG peers (KO/PEP/CL/PG) as the market becomes more comfortable with the sustainability of an improved topline growth outlook.\"</li> <li>MDLZ indicated during the meeting that capital allocation priorities remain returning capital to shareholders through dividends and share repurchases, while keeping an eye on M&amp;A opportunities.</li> <li>Morgan Stanley reiterates an Overweight rating on Mondelez. 16 of 21 sell-side firms covering the stock are in the bull camp and the Quant Rating is also flashing <a href=\"https://seekingalpha.com/symbol/MDLZ/ratings/quant-ratings\" target=\"_blank\">Bullish</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521875\" data-linked=\"Morgan Stanley dials up the conviction on Mondelez International\" data-tweet=\"$MDLZ - Morgan Stanley dials up the conviction on Mondelez International https://seekingalpha.com/news/3521875-morgan-stanley-dials-up-conviction-on-mondelez-international?source=tweet\" data-url=\"https://seekingalpha.com/news/3521875-morgan-stanley-dials-up-conviction-on-mondelez-international\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521872\" data-ts=\"1574706085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPLK\" target=\"_blank\">SPLK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521872-splunkplus-4-on-m-speculation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Splunk +4% on M&amp;A speculation</a></h4><ul><li>Splunk (NASDAQ:<a href='https://seekingalpha.com/symbol/SPLK' title='Splunk Inc.'>SPLK</a>) <font color=\"green\">gains 4.4%</font> to $146.60 after Argus Research says  SPLK \"is exactly the kind of company that could become an acquisition target for a larger enterprise software firm.\"</li><li>Argus maintains a Buy rating and $156 price target. Splunk has a Bullish average <a href=\"https://seekingalpha.com/symbol/SPLK/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521872\" data-linked=\"Splunk +4% on M&amp;A speculation\" data-tweet=\"$SPLK - Splunk +4% on M&amp;A speculation https://seekingalpha.com/news/3521872-splunkplus-4-on-m-speculation?source=tweet\" data-url=\"https://seekingalpha.com/news/3521872-splunkplus-4-on-m-speculation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521871\" data-ts=\"1574705557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521871-ofg-bancorp-leads-financial-gainers-weidai-and-x-financial-only-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OFG Bancorp leads financial gainers; Weidai and X Financial the only losers</a></h4><ul><li><b>Gainers:</b> OFG Bancorp (NYSE:<a href='https://seekingalpha.com/symbol/OFG' title='OFG Bancorp'>OFG</a>) <font color=\"green\">+8%</font>. CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc'>CBL</a>) <font color=\"green\">+7%</font>. Leaf Group (NYSE:<a href='https://seekingalpha.com/symbol/LEAF' title='Leaf Group Ltd.'>LEAF</a>) <font color=\"green\">+7%</font>. eXp World Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/EXPI' title='eXp World Holdings, Inc.'>EXPI</a>) <font color=\"green\">+7%</font>. Leju Holdings (NYSE:<a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a>) <font color=\"green\">+7%</font>.</li><li><b>Losers:</b> Weidai (NYSE:<a href='https://seekingalpha.com/symbol/WEI' title='Weidai Ltd.'>WEI</a>) <font color=\"red\">-8%</font>. X Financial (NYSE:<a href='https://seekingalpha.com/symbol/XYF' title='X Financial'>XYF</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521871\" data-linked=\"OFG Bancorp leads financial gainers; Weidai and X Financial the only losers\" data-tweet=\"$OFG $CBL $LEAF - OFG Bancorp leads financial gainers; Weidai and X Financial the only losers https://seekingalpha.com/news/3521871-ofg-bancorp-leads-financial-gainers-weidai-and-x-financial-only-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521871-ofg-bancorp-leads-financial-gainers-weidai-and-x-financial-only-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521868\" data-ts=\"1574704831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521868-titan-international-and-vertex-energy-among-industrial-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Titan International and Vertex Energy among industrial gainers</a></h4><ul><li><b>Gainers: </b>Research Frontiers (NASDAQ:<a href='https://seekingalpha.com/symbol/REFR' title='Research Frontiers Incorporated'>REFR</a>) <font color=\"green\">+8%</font>. Titan International (NYSE:<a href='https://seekingalpha.com/symbol/TWI' title='Titan International, Inc.'>TWI</a>) <font color=\"green\">+7%</font>. United States Lime &amp; Minerals (NASDAQ:<a href='https://seekingalpha.com/symbol/USLM' title='United States Lime & Minerals, Inc.'>USLM</a>) <font color=\"green\">+7%</font>. TPI Composites (NASDAQ:<a href='https://seekingalpha.com/symbol/TPIC' title='TPI Composites, Inc.'>TPIC</a>) <font color=\"green\">+6%</font>. Vertex Energy (NASDAQ:<a href='https://seekingalpha.com/symbol/VTNR' title='Vertex Energy, Inc.'>VTNR</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers: </b>None</li></ul><div class=\"tiny-share-widget\" data-id=\"3521868\" data-linked=\"Titan International and Vertex Energy among industrial gainers\" data-tweet=\"$REFR $TWI $USLM - Titan International and Vertex Energy among industrial gainers https://seekingalpha.com/news/3521868-titan-international-and-vertex-energy-among-industrial-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521868-titan-international-and-vertex-energy-among-industrial-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521866\" data-ts=\"1574704369\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SURF\" target=\"_blank\">SURF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521866-surface-oncology-receives-25m-in-debt-financing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Surface Oncology receives $25M in debt financing</a></h4><ul><li>Surface Oncology (<a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology, Inc.'>SURF</a> <font color=\"red\">-22.3%</font>) <a href=\"https://seekingalpha.com/pr/17709722-surface-oncology-announces-25-million-debt-financing-k2-healthventures\" target=\"_blank\">secured</a> a debt financing facility for up to $25M from K2 HealthVentures</li><li>Surface received a first tranche of $7.5M upon closing, and two subsequent tranches totaling $17.5M will be available upon the achievement of certain milestones.</li><li>The company projects cash runway into 2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521866\" data-linked=\"Surface Oncology receives $25M in debt financing\" data-tweet=\"$SURF - Surface Oncology receives $25M in debt financing https://seekingalpha.com/news/3521866-surface-oncology-receives-25m-in-debt-financing?source=tweet\" data-url=\"https://seekingalpha.com/news/3521866-surface-oncology-receives-25m-in-debt-financing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521865\" data-ts=\"1574703664\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521865-arwr-kl-admp-and-srne-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ARWR, KL, ADMP and SRNE among midday movers</a></h4><ul><li><strong>Gainers: </strong>JanOne (NASDAQ:<a href='https://seekingalpha.com/symbol/JAN' title='JanOne Inc.'>JAN</a>) <font color=\"green\">+103%</font>.</li><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"green\">+81%</font>.</li><li>The Peck Company (NASDAQ:<a href='https://seekingalpha.com/symbol/PECK' title='The Peck Company Holdings, Inc.'>PECK</a>) <font color=\"green\">+40%</font>.</li><li>RAPT Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RAPT' title='RAPT Therapeutics, Inc.'>RAPT</a>) <font color=\"green\">+28%</font>.</li><li>The Medicines Co. (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>) <font color=\"green\">+22%</font>.</li><li>Aquestive Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics, Inc.'>AQST</a>) <font color=\"green\">+19%</font>.</li><li>Kaleido BioSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/KLDO' title='Kaleido BioSciences, Inc.'>KLDO</a>) <font color=\"green\">+18%</font>.</li><li>Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals, Inc.'>ARWR</a>) <font color=\"green\">+17%</font>.</li><li>NanoViricides (NYSEMKT:<a href='https://seekingalpha.com/symbol/NNVC' title='NanoViricides, Inc.'>NNVC</a>) <font color=\"green\">+16%</font>.</li><li>Kingold Jewelry (NASDAQ:<a href='https://seekingalpha.com/symbol/KGJI' title='Kingold Jewelry, Inc.'>KGJI</a>) <font color=\"green\">+16%</font>.</li><li><strong>Losers: </strong>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) <font color=\"red\">-76%</font>.</li><li>La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Company'>LJPC</a>) <font color=\"red\">-53%</font>.</li><li>Adamis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corporation'>ADMP</a>) <font color=\"red\">-48%</font>.</li><li>ASLAN Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ASLN' title='ASLAN Pharmaceuticals Limited'>ASLN</a>) <font color=\"red\">-29%</font>.</li><li>BlueLinx Holdings (NYSE:<a href='https://seekingalpha.com/symbol/BXC' title='BlueLinx Holdings Inc.'>BXC</a>) <font color=\"red\">-24%</font>.</li><li>Kazia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KZIA' title='Kazia Therapeutics Limited'>KZIA</a>) <font color=\"red\">-20%</font>.</li><li>Surface Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology, Inc.'>SURF</a>) <font color=\"red\">-20%</font>.</li><li>The9 (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) <font color=\"red\">-17%</font>.</li><li>Kirkland Lake Gold (NYSE:<a href='https://seekingalpha.com/symbol/KL' title='Kirkland Lake Gold Ltd.'>KL</a>) <font color=\"red\">-16%</font>.</li><li>Wah Fu Education Group (NASDAQ:<a href='https://seekingalpha.com/symbol/WAFU' title='Wah Fu Education Group Limited'>WAFU</a>) <font color=\"red\">-16%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521865\" data-linked=\"ARWR, KL, ADMP and SRNE among midday movers\" data-tweet=\"$JAN $SRNE $PECK - ARWR, KL, ADMP and SRNE among midday movers https://seekingalpha.com/news/3521865-arwr-kl-admp-and-srne-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521865-arwr-kl-admp-and-srne-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521864\" data-ts=\"1574703413\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLL\" target=\"_blank\">FLL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521864-full-house-resorts-pops-after-gabelli-mention\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Full House Resorts pops after Gabelli mention</a></h4><ul> <li>Trading on Full House Resorts (<a href='https://seekingalpha.com/symbol/FLL' title='Full House Resorts, Inc.'>FLL</a> <font color='green'>+19.7%</font>) has been halted after a mention on CNBC by Mario Gabelli of the stock as a potential gaming play sent shares flying.</li> <li>The Nasdaq trading halt was due to volatility.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521864\" data-linked=\"Full House Resorts pops after Gabelli mention\" data-tweet=\"$FLL - Full House Resorts pops after Gabelli mention https://seekingalpha.com/news/3521864-full-house-resorts-pops-after-gabelli-mention?source=tweet\" data-url=\"https://seekingalpha.com/news/3521864-full-house-resorts-pops-after-gabelli-mention\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521863\" data-ts=\"1574703109\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CTSO\" target=\"_blank\">CTSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521863-cytosorbents-to-stop-patient-enrollment-in-refresh-2-aki-trial\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CytoSorbents to stop patient enrollment in REFRESH 2-AKI trial</a></h4><ul><li>CytoSorbents (<a href='https://seekingalpha.com/symbol/CTSO' title='Cytosorbents Corporation'>CTSO</a> <font color='red'>-7.6%</font>) sinks to a 52-week low after saying it is <a href=\"https://seekingalpha.com/pr/17709585-cytosorbents-changes-contract-research-organizations-temporarily-pauses-enrollment-refresh-2\" target=\"_blank\">pausing enrollment</a> of its REFRESH 2-AKI study following a blinded, interim, milestone review of clinical study data by its data monitoring committee.</li><li>CTSO says there were no specific adverse events of clinical outcomes cited in the committee's initial recommendations, but additional data analysis and clinical data were needed to improve the monitoring of patient safety endpoints.</li><li>During the pause, CTSO says it will focus its clinical and financial resources to accelerate its clinical trial strategy to obtain FDA approval of its flagship CytoSorb product for other specific applications.</li><li>The REFRESH 2-AKI trial was  evaluating the use of two CytoSorb cartridges in parallel during  cardiac surgery to reduce the incidence or severity of acute kidney  injury 48 hours after surgery in two select populations.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521863\" data-linked=\"CytoSorbents to stop patient enrollment in REFRESH 2-AKI trial\" data-tweet=\"$CTSO - CytoSorbents to stop patient enrollment in REFRESH 2-AKI trial https://seekingalpha.com/news/3521863-cytosorbents-to-stop-patient-enrollment-in-refresh-2-aki-trial?source=tweet\" data-url=\"https://seekingalpha.com/news/3521863-cytosorbents-to-stop-patient-enrollment-in-refresh-2-aki-trial\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521861\" data-ts=\"1574702637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521861-facebook-launches-market-research-app\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook launches market research app</a></h4><ul><li>Facebook (<a href='https://seekingalpha.com/symbol/FB' title='Facebook, Inc.'>FB</a> <font color='green'>+0.9%</font>) <a href=\"https://www.streetinsider.com/Corporate+News/Facebook+%28FB%29+Introduces+Facebook+Viewpoints/16175930.html\" target=\"_blank\">launches</a> Viewpoints, which rewards users for participating in surveys and research.</li><li>FB says it will use the \"insights to improve products like Facebook, Instagram, WhatsApp, Portal and Oculus, and to benefit the broader community.\"</li><li>The company says it won't sell Viewpoints data to third-party apps and won't publicly share Viewpoints activity on Facebook or other linked accounts without the user's permission.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521861\" data-linked=\"Facebook launches market research app\" data-tweet=\"$FB - Facebook launches market research app https://seekingalpha.com/news/3521861-facebook-launches-market-research-app?source=tweet\" data-url=\"https://seekingalpha.com/news/3521861-facebook-launches-market-research-app\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521855\" data-ts=\"1574701664\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521855-nvidiaplus-4_5-morgan-stanley-turns-bullish\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nvidia +4.5% as Morgan Stanley turns bullish</a></h4><ul><li>Morgan Stanley upgrades Nvidia (NASDAQ:<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a>) from Equal Weight to Overweight. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/NVDA/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li><li>The firm cites a \"return to solid growth\" for the gaming and data center businesses.</li><li>Analyst Joseph Moore sees NVDA positioned for potential upside across 2020.</li><li>Morgan Stanley raises its Nvidia target from $217 to $259.</li><li>NVDA shares are <font color=\"green\">up 4.5%</font> to $220.27.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521855\" data-linked=\"Nvidia +4.5% as Morgan Stanley turns bullish\" data-tweet=\"$NVDA - Nvidia +4.5% as Morgan Stanley turns bullish https://seekingalpha.com/news/3521855-nvidiaplus-4_5-morgan-stanley-turns-bullish?source=tweet\" data-url=\"https://seekingalpha.com/news/3521855-nvidiaplus-4_5-morgan-stanley-turns-bullish\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521853\" data-ts=\"1574701472\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521853-tenneco-and-cresud-among-consumer-gainers-funko-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tenneco and Cresud among consumer gainers; Funko among losers</a></h4><ul><li><b>Gainers: </b>Cresud Sociedad (NASDAQ:<a href='https://seekingalpha.com/symbol/CRESY' title='Cresud Sociedad Anónima Comercial, Inmobiliaria, Financiera y Agropecuaria'>CRESY</a>) <font color=\"green\">+12%</font>. Schweitzer-Mauduit International (NYSE:<a href='https://seekingalpha.com/symbol/SWM' title='Schweitzer-Mauduit International, Inc.'>SWM</a>) <font color=\"green\">+6%</font>. Resolute Forest Products (NYSE:<a href='https://seekingalpha.com/symbol/RFP' title='Resolute Forest Products Inc.'>RFP</a>) <font color=\"green\">+6%</font>. Tenneco (NYSE:<a href='https://seekingalpha.com/symbol/TEN' title='Tenneco Inc.'>TEN</a>) <font color=\"green\">+5%</font>. Cooper-Standard (NYSE:<a href='https://seekingalpha.com/symbol/CPS' title='Cooper-Standard Holdings Inc.'>CPS</a>) <font color=\"green\">+5%</font>.</li><li><b>Losers: </b>Koss (NASDAQ:<a href='https://seekingalpha.com/symbol/KOSS' title='Koss Corporation'>KOSS</a>) <font color=\"red\">-8%</font>. U.S. Auto Parts Network (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTS' title='U.S. Auto Parts Network, Inc.'>PRTS</a>) <font color=\"red\">-6%</font>. Funko (NASDAQ:<a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a>) <font color=\"red\">-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521853\" data-linked=\"Tenneco and Cresud among consumer gainers; Funko among losers\" data-tweet=\"$CRESY $SWM $RFP - Tenneco and Cresud among consumer gainers; Funko among losers https://seekingalpha.com/news/3521853-tenneco-and-cresud-among-consumer-gainers-funko-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521853-tenneco-and-cresud-among-consumer-gainers-funko-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521850\" data-ts=\"1574701232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DECK\" target=\"_blank\">DECK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521850-wells-fargo-sees-headwinds-building-for-deckers-outdoor\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wells Fargo sees headwinds building for Deckers Outdoor</a></h4><ul> <li>Wells Fargo upgrades Deckers Outdoor (<a href='https://seekingalpha.com/symbol/DECK' title='Deckers Outdoor Corporation'>DECK</a> <font color='green'>+2.6%</font>) to an Outperform rating after having the retailer slotted at Market Perform.</li> <li>\"We believe that the 2H20 weather outlook is improving, presenting upside potential to guidance (which embeds meaningful margin/EPS headwinds from weather). At a higher level, we believe DECK has a compelling portfolio structure, with a 'cash cow' UGG brand that is benefiting from a strengthening/diversified assortment, funding expansion of 2 key growth brands: Hoka and Koolaburra.\"</li> <li>The firm thinks the Koolaburra business could grow 4X to 5X to $325M to $350M in annual revenue and add $1.50 to EPS by 2024.</li> <li>WF's price target of $195 on Deckers reps around 20% upside potential and is above the <a href=\"https://seekingalpha.com/symbol/DECK/ratings/sell-side-ratings\" target=\"_blank\">sell-side average PT</a> of $$184.59.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521850\" data-linked=\"Wells Fargo sees headwinds building for Deckers Outdoor\" data-tweet=\"$DECK - Wells Fargo sees headwinds building for Deckers Outdoor https://seekingalpha.com/news/3521850-wells-fargo-sees-headwinds-building-for-deckers-outdoor?source=tweet\" data-url=\"https://seekingalpha.com/news/3521850-wells-fargo-sees-headwinds-building-for-deckers-outdoor\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521849\" data-ts=\"1574701084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521849-amd-teases-64-core-threadripper-sharesplus-2_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD teases 64-core Threadripper; shares +2.3%</a></h4><ul><li>AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) teases the Ryzen Threadripper 3990X, which will launch next year.</li><li>A leaked <a href=\"https://videocardz.com/newz/amd-to-launch-ryzen-threadripper-3990x-with-64-cores-in-2020\" target=\"_blank\">presentation slide</a> shows some base specs: 64 cores, 128 threads, 288MB of total cache, and a TDP of 280W.</li><li>The reveal comes as <a href=\"https://www.pcmag.com/review/372078/amd-ryzen-threadripper-3970x\" target=\"_blank\">positive reviews</a> for the new Ryzen Threadripper 3970X start to roll in.</li><li>AMD shares are <font color=\"red\">up 2.3%</font> to $40.05.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521849\" data-linked=\"AMD teases 64-core Threadripper; shares +2.3%\" data-tweet=\"$AMD - AMD teases 64-core Threadripper; shares +2.3% https://seekingalpha.com/news/3521849-amd-teases-64-core-threadripper-sharesplus-2_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3521849-amd-teases-64-core-threadripper-sharesplus-2_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>124&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521830\" data-ts=\"1574698804\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VAL\" target=\"_blank\">VAL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521830-valaris-discloses-18_7-active-stake-luminus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valaris discloses 18.7% active stake by Luminus</a></h4><ul><li>Valaris (<a href='https://seekingalpha.com/symbol/VAL' title='Valaris plc'>VAL</a> <font color='green'>+8.2%</font>) is on the move after shareholder Luminus Management says it owns an <a href=\"https://www.sec.gov/Archives/edgar/data/314808/000090266419004424/p19-2198sc13d.htm\" target=\"_blank\">18.7% active stake</a> in the company; the investment advisor had owned a 4.5% holding as of a <a href=\"https://seekingalpha.com/pr/17542329-luminus-management-sends-proposal-enscorowan-plc-board-directors\" target=\"_blank\">June 12 press release</a>.</li><li>Luminus also sends a <a href=\"https://www.sec.gov/Archives/edgar/data/314808/000090266419004424/p19-2198exhibit3.htm\" target=\"_blank\">letter to VAL's board</a> advising not to enter into any debt capital markets transactions for the time being and refrain from \"any corporate machinations that impact the ability of stockholders... to buy Valaris stock, vote their stake or have a say in the future of the company.\"</li><li>\"After months of fruitless discussions between the company and our firm, we want to reiterate our perspectives and call upon you to act,\" Luminus says.</li><li>VAL has been evaluating a <a href=\"https://seekingalpha.com/news/3470814-ensco-rowan-investor-urges-2_5b-special-dividend-payout\" target=\"_blank\">proposal from Luminus</a> for a  $2.5B bond  offering to fund a special dividend, after the investment  manager  earlier said it was disappointed with the company's stock performance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521830\" data-linked=\"Valaris discloses 18.7% active stake by Luminus\" data-tweet=\"$VAL - Valaris discloses 18.7% active stake by Luminus https://seekingalpha.com/news/3521830-valaris-discloses-18_7-active-stake-luminus?source=tweet\" data-url=\"https://seekingalpha.com/news/3521830-valaris-discloses-18_7-active-stake-luminus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521827\" data-ts=\"1574697811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521827-healthcare-top-5-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers</a></h4><ul><li><b>Gainers: </b>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"green\">+52%</font>. The Medicines Co. (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>) <font color=\"green\">+22%</font>. Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals, Inc.'>ARWR</a>) <font color=\"green\">+19%</font>. BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) <font color=\"green\">+15%</font>. Aquestive Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics, Inc.'>AQST</a>) <font color=\"green\">+14%</font>.</li><li><b>Losers: </b>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) <font color=\"red\">-76%</font>. La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Company'>LJPC</a>) <font color=\"red\">-55%</font>. Adamis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corporation'>ADMP</a>) <font color=\"red\">-49%</font>. ASLAN Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ASLN' title='ASLAN Pharmaceuticals Limited'>ASLN</a>) <font color=\"red\">-33%</font>. Kazia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KZIA' title='Kazia Therapeutics Limited'>KZIA</a>) <font color=\"red\">-18%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521827\" data-linked=\"Healthcare - Top 5 Gainers / Losers\" data-tweet=\"$SRNE $MDCO $ARWR - Healthcare - Top 5 Gainers / Losers https://seekingalpha.com/news/3521827-healthcare-top-5-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521827-healthcare-top-5-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521826\" data-ts=\"1574697656\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNKO\" target=\"_blank\">FNKO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521826-funko-slides-after-piper-jaffray-pt-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Funko slides after Piper Jaffray PT cut</a></h4><ul><li>Piper Jaffray reels in its price target on Overweight-rated Funko (<a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a> <font color='red'>-6.4%</font>) to $24 from $30 adjust for lowered estimates. The Piper analyst team made the adjustment after meeting with Funko management.</li><li>The new PT is below the average sell-side PT of $26.33.</li><li>Funko has traded as low as $13.93 in today's session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521826\" data-linked=\"Funko slides after Piper Jaffray PT cut\" data-tweet=\"$FNKO - Funko slides after Piper Jaffray PT cut https://seekingalpha.com/news/3521826-funko-slides-after-piper-jaffray-pt-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3521826-funko-slides-after-piper-jaffray-pt-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521820\" data-ts=\"1574697146\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LRCX\" target=\"_blank\">LRCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521820-lam-target-boosted-on-compelling-setup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lam target boosted on &#39;compelling&#39; setup</a></h4><ul><li>KeyBanc raises its Lam Research (<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color=\"green\">+2.6%</font>) price target from $261 to $313.</li><li>Analyst Weston Twigg cites the company's \"compelling\" setup ahead of next year's expected fab equipment demand growth. The rebound could start in Q2.</li><li>Twigg has \"high conviction regarding LRCX outperformance as tailwinds accelerate\" due to fundamental drivers and execution strength.</li><li>KeyBanc reiterates an Overweight rating on Lam. The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/LRCX/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521820\" data-linked=\"Lam target boosted on &#39;compelling&#39; setup\" data-tweet=\"$LRCX - Lam target boosted on &#39;compelling&#39; setup https://seekingalpha.com/news/3521820-lam-target-boosted-on-compelling-setup?source=tweet\" data-url=\"https://seekingalpha.com/news/3521820-lam-target-boosted-on-compelling-setup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521819\" data-ts=\"1574697026\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEVA\" target=\"_blank\">TEVA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521819-teva-in-talks-doj-to-end-generics-probe-bloomberg\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Teva in talks with DoJ to end generics probe - Bloomberg</a></h4><ul><li>Teva Pharmaceuticals (<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a> <font color=\"green\">+6.5%</font>) pops higher in morning trade following a Bloomberg report that it has held talks with the U.S. Department of Justice about <a href=\"https://www.bloomberg.com/news/articles/2019-11-25/teva-other-drugmakers-in-talks-with-u-s-to-end-generics-probes\" target=\"_blank\">resolving a criminal antitrust probe</a> of alleged price-fixing by the companies, Bloomberg reports.</li><li>A unit of Indian generics giant Sun Pharmaceutical also has been in talks with federal prosecutors, Bloomberg reports.</li><li>Among possible outcomes that have been discussed are deferred  prosecution agreements in which the companies would admit to certain  allegations but would be shielded from indictment in exchange for  cooperating with the investigation and paying fines, according to the report.</li><li>Prosecutors have been probing allegations that generic drugmakers  conspired to prop up the prices of certain widely used medications for  more than five years and have hinted several times this year that  charges could be imminent.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521819\" data-linked=\"Teva in talks with DoJ to end generics probe - Bloomberg\" data-tweet=\"$TEVA - Teva in talks with DoJ to end generics probe - Bloomberg https://seekingalpha.com/news/3521819-teva-in-talks-doj-to-end-generics-probe-bloomberg?source=tweet\" data-url=\"https://seekingalpha.com/news/3521819-teva-in-talks-doj-to-end-generics-probe-bloomberg\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521809\" data-ts=\"1574694373\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TAP\" target=\"_blank\">TAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521809-barclays-cools-on-molson-coors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays cools on Molson Coors</a></h4><ul> <li>Barclays says it's taking a wait-and-see approach with Molson Coors (<a href='https://seekingalpha.com/symbol/TAP' title='Molson Coors Brewing Company'>TAP</a> <font color='red'>-0.2%</font>) due to the recent track record of disappointments.</li> <li>\"We continue to appreciate the newfound urgency and creativity with which TAP has been working to improve top-line trends across its portfolio over the last 6 months and view the growth agenda within the newly announced 'revitalization plan' as a welcome extension of this. Still, there have been too many disappointments for too long and we worry that the company's approach of doing very little hand-holding with regard to near term guidance will mean improved revenue trends will need to be apparent before investors are willing to re-engage with the story.\"</li> <li>The firm <a href=\"https://www.streetinsider.com/Analyst+Comments/Barclays+Downgrades+Molson+Coors+%28TAP%29+to+Equalweight%2C+Believes+Investors+Will+Await+Clarity/16174181.html\" target=\"_blank\">lowers</a> TAP to an Equal-weight rating from Overweight. The average sell-side <a href=\"https://seekingalpha.com/symbol/TAP/ratings/sell-side-ratings\" target=\"_blank\">rating</a> and Quant Rating on TAP are also at Neutral.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521809\" data-linked=\"Barclays cools on Molson Coors\" data-tweet=\"$TAP - Barclays cools on Molson Coors https://seekingalpha.com/news/3521809-barclays-cools-on-molson-coors?source=tweet\" data-url=\"https://seekingalpha.com/news/3521809-barclays-cools-on-molson-coors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521808\" data-ts=\"1574694337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521808-bull-sees-2020-upsides-for-mu-wdc\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bull sees 2020 upsides for MU, WDC</a></h4><ul><li>Longbow Research sees an improved outlook for chip stocks in 2020, which should lift Micron (<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology, Inc.'>MU</a> <font color='green'>+1.1%</font>) and Western Digital (<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a> <font color='green'>+1.6%</font>) in H1.</li><li>Analyst Nikolay Todorov sees an upside to consensus in H2, \"driven by outlook of persistent undersupply, supporting strong pricing and margin expansion.\"</li><li>Longbow has Buy ratings on MU and WDC with targets of $60 and $70, respectively.</li><li><a href=\"https://seekingalpha.com/symbol/MU/ratings/sell-side-ratings\" target=\"_blank\">Micron</a> and <a href=\"https://seekingalpha.com/symbol/WDC/ratings/sell-side-ratings?s=wdc\" target=\"_blank\">Western Digital</a> have Bullish average Sell Side ratings.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521808\" data-linked=\"Bull sees 2020 upsides for MU, WDC\" data-tweet=\"$MU $WDC - Bull sees 2020 upsides for MU, WDC https://seekingalpha.com/news/3521808-bull-sees-2020-upsides-for-mu-wdc?source=tweet\" data-url=\"https://seekingalpha.com/news/3521808-bull-sees-2020-upsides-for-mu-wdc\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>132&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521802\" data-ts=\"1574693932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMC\" target=\"_blank\">AMC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521802-amc-entertainment-rallies-after-big-frozen-2-weekend\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMC Entertainment rallies after big Frozen 2 weekend</a></h4><ul> <li>AMC Entertainment (NYSE:<a href='https://seekingalpha.com/symbol/AMC' title='AMC Entertainment Holdings, Inc.'>AMC</a>) <font color=\"green\">jumps 4.21%</font> in morning trading after Frozen 2 opens with $127M in the U.S. and $350M globally to top expectations.</li> <li>The Disney film earned a CinemaScore of A-, indicating it could have some legs for a while.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3521685-frozen-ii-sets-disney-records\" target=\"_blank\">'Frozen II' sets more Disney records</a> (Nov. 25)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521802\" data-linked=\"AMC Entertainment rallies after big Frozen 2 weekend\" data-tweet=\"$AMC - AMC Entertainment rallies after big Frozen 2 weekend https://seekingalpha.com/news/3521802-amc-entertainment-rallies-after-big-frozen-2-weekend?source=tweet\" data-url=\"https://seekingalpha.com/news/3521802-amc-entertainment-rallies-after-big-frozen-2-weekend\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521797\" data-ts=\"1574693468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WING\" target=\"_blank\">WING</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521797-baird-returns-to-wingstop-bull-camp\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird returns to Wingstop bull camp</a></h4><ul> <li>Wingstop (<a href='https://seekingalpha.com/symbol/WING' title='Wingstop Inc.'>WING</a> <font color='green'>+3.2%</font>) gains after Baird says valuation on the restaurant stock looks appetizing once again.</li> <li>Baird moves to an Outperform rating from Market Perform and keeps a price target of $92. The average sell-side PT on Wingstop is <a href=\"https://seekingalpha.com/symbol/WING/ratings/sell-side-ratings\" target=\"_blank\">$98.93</a>.</li> <li>Shares of Wingstop peeled back 26% over the last three months after a steady two-year rally.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521797\" data-linked=\"Baird returns to Wingstop bull camp\" data-tweet=\"$WING - Baird returns to Wingstop bull camp https://seekingalpha.com/news/3521797-baird-returns-to-wingstop-bull-camp?source=tweet\" data-url=\"https://seekingalpha.com/news/3521797-baird-returns-to-wingstop-bull-camp\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521796\" data-ts=\"1574693397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521796-pareteumplus-8-after-ceo-termination\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +8% after CEO termination</a></h4><ul><li>Pareteum (NASDAQ:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) terminates Robert Turner as CEO and Chairman and appoints Bart Weijermars as interim CEO while retaining his role as Chief Strategy Officer.</li><li>Independent Director Mary Beth Vitale will serve as board chair for the transition period.</li><li>TEUM makes the changes as it works to complete its restatement process and improve its financial and operational controls.</li><li>Pareteum shares are <font color=\"green\">up 8.4%</font> to $0.46.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521796\" data-linked=\"Pareteum +8% after CEO termination\" data-tweet=\"$TEUM - Pareteum +8% after CEO termination https://seekingalpha.com/news/3521796-pareteumplus-8-after-ceo-termination?source=tweet\" data-url=\"https://seekingalpha.com/news/3521796-pareteumplus-8-after-ceo-termination\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521794\" data-ts=\"1574692725\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NFLX\" target=\"_blank\">NFLX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521794-new-netflix-bear-steps-out\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Netflix bear steps out</a></h4><ul> <li>Wells Fargo sours on Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='red'>-0.3%</font>) in the face of new streaming competition.</li> <li>\"We think NFLX can achieve the street's sub growth expectations but those subs will be more expensive than investors realize,\" writes analyst Steven Cahall.</li> <li>After a deep dive into Netflix's cash estimate, Cahall and team issue a free cash forecast about $18B below where the Street consensus stands.</li> <li>\"We don\u2019t doubt NFLX will eventually turn a cash profit with arrows in the quiver like cracking down on password sharing, curtailing content spend or even advertising. But all of these indicate a more mature growth business likely with a lower multiple.\"</li> <li>Wells Fargo lowers Netflix to an Underperform rating from Market Perform and assigns a price target of $265.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521794\" data-linked=\"New Netflix bear steps out\" data-tweet=\"$NFLX - New Netflix bear steps out https://seekingalpha.com/news/3521794-new-netflix-bear-steps-out?source=tweet\" data-url=\"https://seekingalpha.com/news/3521794-new-netflix-bear-steps-out\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>34&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521793\" data-ts=\"1574692644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SAEX\" target=\"_blank\">SAEX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521793-saexploration-gets-nasdaq-non-compliance-letter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SAExploration gets Nasdaq non-compliance letter</a></h4><ul><li>SAExploration (<a href='https://seekingalpha.com/symbol/SAEX' title='SAExploration Holdings, Inc.'>SAEX</a> <font color='red'>-9.8%</font>) says it is <a href=\"https://seekingalpha.com/pr/17709206-saexploration-announces-receipt-nasdaq-non-compliance-letter\" target=\"_blank\">not in compliance</a> with Nasdaq listing rules after failing to meet the requirement for timely filing of all public financial reports.</li><li>SAEX did not file its 10-Q report for the quarter ended Sept. 30 and remains delinquent in filing its 10-Q for the June quarter.</li><li>The Nasdaq non-compliance notice says the company has until Dec. 17 to submit an updated plan to regain compliance; if the plan is accepted, Nasdaq may grant up to 180 days to file the June quarter 10-Q, or until Feb. 11, 2020, to regain compliance.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521793\" data-linked=\"SAExploration gets Nasdaq non-compliance letter\" data-tweet=\"$SAEX - SAExploration gets Nasdaq non-compliance letter https://seekingalpha.com/news/3521793-saexploration-gets-nasdaq-non-compliance-letter?source=tweet\" data-url=\"https://seekingalpha.com/news/3521793-saexploration-gets-nasdaq-non-compliance-letter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521791\" data-ts=\"1574692178\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521791-mdco-tif-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MDCO, TIF among premarket gainers</a></h4><ul><li>JanOne (NASDAQ:<a href='https://seekingalpha.com/symbol/JAN' title='JanOne Inc.'>JAN</a>) <font color=\"green\">+127%</font> on <a href=\"https://seekingalpha.com/pr/17709957-janone-acquires-worldwide-exclusive-license-promising-treatment-peripheral-arterial-disease\" target=\"_blank\">acquiring</a> worldwide license for treatment of Peripheral Arterial Disease.</li><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"green\">+38% </font>on <a href=\"https://seekingalpha.com/news/3521723-sorrento-received-rejected-unsolicited-acquisition-proposal\" target=\"_blank\">rejecting</a> an unsolicited buyout proposal from two unnamed biopharma companies.</li><li>The Medicines (NASDAQ:<a href='https://seekingalpha.com/symbol/MDCO' title='The Medicines Company'>MDCO</a>) <font color=\"green\">+23% </font>on being <a href=\"https://seekingalpha.com/news/3521670-novartis-inks-9_7b-deal-medicines-co\" target=\"_blank\">acquired</a> by Novartis.</li><li>LiveXLive Media (NASDAQ:<a href='https://seekingalpha.com/symbol/LIVX' title='LiveXLive Media, Inc.'>LIVX</a>) <font color=\"green\">+23%</font> on announce production And distribution <a href=\"https://seekingalpha.com/pr/17709803-livexlive-samsung-announce-production-distribution-partnership\" target=\"_blank\">partnership with Samsung</a> (<a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>).</li><li>Enochian Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ENOB' title='Enochian Biosciences Inc.'>ENOB</a>) <font color=\"green\">+18%</font> on <a href=\"https://seekingalpha.com/news/3521777-enochian-bio-plus-18-percent-premarket-acquiring-exclusive-license-hbv\" target=\"_blank\">acquiring</a> exclusive license for HBV.</li><li>Aquestive Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/AQST' title='Aquestive Therapeutics, Inc.'>AQST</a>) <font color=\"green\">+12%</font> after FDA <a href=\"https://seekingalpha.com/news/3521664-aquestive-plus-14-percent-fda-approves-exservan-als-film\" target=\"_blank\">approves</a> Exservan ALS film.</li><li>AnaptysBio (NASDAQ:<a href='https://seekingalpha.com/symbol/ANAB' title='AnaptysBio, Inc.'>ANAB</a>) <font color=\"green\">+12%</font>.</li><li>Niu Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/NIU' title='Niu Technologies'>NIU</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/news/3521689-niu-technologies-eps-beats-0_07-beats-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li>UP Fintech Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/TIGR' title='UP Fintech Holding Limited'>TIGR</a>) <font color=\"green\">+9%</font> on <a href=\"https://seekingalpha.com/news/3521695-fintech-reports-q3-results\" target=\"_blank\">Q3 earnings</a>.</li><li>Proteostasis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics, Inc.'>PTI</a>) <font color=\"green\">+7%</font>.</li><li>My Size (NASDAQ:<a href='https://seekingalpha.com/symbol/MYSZ' title='My Size, Inc.'>MYSZ</a>) <font color=\"green\">+6%</font>.</li><li>ZIOPHARM Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) <font color=\"green\">+6%</font>.</li><li>eBay (NASDAQ:<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a>) <font color=\"green\">+6%</font> after <a href=\"https://seekingalpha.com/news/3521779-ebay-plus-6-percent-selling-stubhub\" target=\"_blank\">selling</a> StubHub.</li><li>Tiffany &amp; Co. (NYSE:<a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a>) <font color=\"green\">+6%</font> after striking a <a href=\"https://seekingalpha.com/news/3521748-luxury-sector-shakeup-sends-investors-scrambling\" target=\"_blank\">buyout deal</a> with LVMH (<a href='https://seekingalpha.com/symbol/LVMHF' title='LVMH Moët Hennessy - Louis Vuitton, Société Européenne'>OTCPK:LVMHF</a>).</li><li>Intercept Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ICPT' title='Intercept Pharmaceuticals, Inc.'>ICPT</a>) <font color=\"green\">+5%</font> after <a href=\"https://seekingalpha.com/news/3521756-fda-oks-intercept-s-nda-obeticholic-acid-shares-5-percent-premarket\" target=\"_blank\">FDA OKs</a> NDA for obeticholic acid.</li><li>Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals, Inc.'>ARWR</a>) <font color=\"green\">+5%</font> after Medicines Co. <a href=\"https://seekingalpha.com/news/3521781-arrowhead-pharma-5-percent-medicines-co-sale\" target=\"_blank\">sale</a>.</li><li>Teva Pharmaceutical Industries (NYSE:<a href='https://seekingalpha.com/symbol/TEVA' title='Teva Pharmaceutical Industries Limited'>TEVA</a>) <font color=\"green\">+5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521791\" data-linked=\"MDCO, TIF among premarket gainers\" data-tweet=\"$JAN $SRNE $MDCO - MDCO, TIF among premarket gainers https://seekingalpha.com/news/3521791-mdco-tif-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521791-mdco-tif-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521789\" data-ts=\"1574691840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LIVX\" target=\"_blank\">LIVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521789-livexliveplus-23-on-samsung-tie-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">LiveXLive +23% on Samsung tie-up</a></h4><ul><li>LiveXLive Media (NASDAQ:<a href='https://seekingalpha.com/symbol/LIVX' title='LiveXLive Media, Inc.'>LIVX</a>) <font color=\"green\">gains 22.6%</font> pre-market to $1.90 <a href=\"https://seekingalpha.com/pr/17709803-livexlive-samsung-announce-production-distribution-partnership\" target=\"_blank\">after announcing</a> its content will be available on Samsung's (<a href='https://seekingalpha.com/symbol/SSNLF' title='Samsung Electronics Co., Ltd.'>OTC:SSNLF</a>) XR platform.</li><li>LiveXLive in Samsung XR will offer music events with holographics, volumetric video, and on-site AR.</li><li>The companies plan to collaborate and bring music and tech products to all Samsung devices.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521789\" data-linked=\"LiveXLive +23% on Samsung tie-up\" data-tweet=\"$LIVX $LIVX $SSNLF - LiveXLive +23% on Samsung tie-up https://seekingalpha.com/news/3521789-livexliveplus-23-on-samsung-tie-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3521789-livexliveplus-23-on-samsung-tie-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521785\" data-ts=\"1574691456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521785-kl-cbay-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KL, CBAY among premarket losers</a></h4><ul><li>CymaBay Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a>) <font color=\"red\">-75%</font> on <a href=\"https://seekingalpha.com/news/3521751-cymabay-halts-trial-seladelpar-shares-dip-4-percent\" target=\"_blank\">halting trial</a> of seladelpar.</li><li>Adamis Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corporation'>ADMP</a>) <font color=\"red\">-56%</font> on FDA's <a href=\"https://seekingalpha.com/news/3521768-adamis-pharma-minus-61-percent-fdas-zimhi-rejection\" target=\"_blank\">Zimhi rejection</a>.</li><li>La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Company'>LJPC</a>) <font color=\"red\">-39%</font> on <a href=\"https://seekingalpha.com/news/3521780-la-jolla-pharma-reassess-development-ljpcminus-401\" target=\"_blank\">reassessing</a> development of LJPC-401.</li><li>ASLAN Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ASLN' title='ASLAN Pharmaceuticals Limited'>ASLN</a>) <font color=\"red\">-27%</font>.</li><li>Kirkland Lake Gold (NYSE:<a href='https://seekingalpha.com/symbol/KL' title='Kirkland Lake Gold Ltd.'>KL</a>) <font color=\"red\">-12%</font> on announcing <a href=\"https://seekingalpha.com/news/3521715-kirkland-lake-gold-buy-detour-gold-c-4_9b-deal\" target=\"_blank\">acquisition</a> of Detour Gold for C$4.9B.</li><li>Kazia Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/KZIA' title='Kazia Therapeutics Limited'>KZIA</a>) <font color=\"red\">-11%</font>.</li><li>22nd Century Group (NYSEMKT:<a href='https://seekingalpha.com/symbol/XXII' title='22nd Century Group, Inc.'>XXII</a>) <font color=\"red\">-6%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521785\" data-linked=\"KL, CBAY among premarket losers\" data-tweet=\"$CBAY $ADMP $LJPC - KL, CBAY among premarket losers https://seekingalpha.com/news/3521785-kl-cbay-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3521785-kl-cbay-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521781\" data-ts=\"1574690972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARWR\" target=\"_blank\">ARWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521781-arrowhead-pharma-up-5-after-medicines-co-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arrowhead Pharma up 5% after Medicines Co. sale</a></h4><ul><li>Baird <a href=\"https://twitter.com/jfais20/status/1198938933725261825\" target=\"_blank\">upgrades</a> Arrowhead Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals, Inc.'>ARWR</a>) to Outperform with $70 price target (<font color=\"green\">40% upside</font>), noting Novartis' <a href=\"https://seekingalpha.com/news/3521670-novartis-inks-9_7b-deal-medicines-co\" target=\"_blank\">purchase of</a> The Medicines Company means a re-evaluation of ARWR's  RNAi platform.</li><li>Shares are <font color=\"green\">up 5.3%</font> to $49.20 premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521781\" data-linked=\"Arrowhead Pharma up 5% after Medicines Co. sale\" data-tweet=\"$ARWR - Arrowhead Pharma up 5% after Medicines Co. sale https://seekingalpha.com/news/3521781-arrowhead-pharma-up-5-after-medicines-co-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3521781-arrowhead-pharma-up-5-after-medicines-co-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521780\" data-ts=\"1574690950\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521780-la-jolla-pharma-to-reassess-development-of-ljpcminus-401\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">La Jolla Pharma to reassess development of LJPC-401</a></h4><ul><li>La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Company'>LJPC</a>) <font color=\"red\">-37.3%</font> pre-market following news that it will <a href=\"https://seekingalpha.com/pr/17709896-la-jolla-reassess-continued-development-ljpcminus-401-based-recent-clinical-results\" target=\"_blank\">reassess continued development</a> of LJPC-401 (synthetic human hepcidin), its lead investigational product for the potential treatment of conditions characterized by iron overload, based on recent mixed clinical results.</li><li>The company says it now will focus on maximizing sales of Giapreza (angiotensin II) as a vasoconstrictor indicated to increase blood  pressure in adults with septic or other distributive shock in the U.S., and maximizing the value of Giapreza for the treatment of refractory  hypotension in adults with septic or other distributive shock.</li><li>LJPC also says President and CEO George Tidmarsh has <a href=\"https://seekingalpha.com/pr/17709864-la-jolla-pharmaceutical-company-announces-management-transition\" target=\"_blank\">left the company</a> to pursue other interests; while it launches a search for a new CEO, board members Kevin Tang and Craig Johnson will provide management oversight.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521780\" data-linked=\"La Jolla Pharma to reassess development of LJPC-401\" data-tweet=\"$LJPC - La Jolla Pharma to reassess development of LJPC-401 https://seekingalpha.com/news/3521780-la-jolla-pharma-to-reassess-development-of-ljpcminus-401?source=tweet\" data-url=\"https://seekingalpha.com/news/3521780-la-jolla-pharma-to-reassess-development-of-ljpcminus-401\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521779\" data-ts=\"1574690941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EBAY\" target=\"_blank\">EBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521779-ebayplus-6-after-selling-stubhub\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EBay +6% after selling StubHub</a></h4><ul> <li>EBay (NASDAQ:<a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a>) confirms it sold StubHub to viagogo for $4.05 billion in cash.</li>                  <li>\"We believe this transaction is a great outcome and maximizes long-term value for eBay shareholders,\" says interim CEO Scott Schenkel.</li><li>The sale was highly anticipated and followed a board review of eBay's strategies and portfolio.</li><li>The sale is expected to close by the end of Q1 of 2020, subject to regulatory approval and customary closing conditions.</li>  <li>EBAY  <font color=\"green\">+6.06%</font> premarket to  $37.25.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17710035-viagogo-acquires-stubhub-ebay-4_05-billion\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3521779\" data-linked=\"EBay +6% after selling StubHub\" data-tweet=\"$EBAY - EBay +6% after selling StubHub https://seekingalpha.com/news/3521779-ebayplus-6-after-selling-stubhub?source=tweet\" data-url=\"https://seekingalpha.com/news/3521779-ebayplus-6-after-selling-stubhub\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521777\" data-ts=\"1574690748\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENOB\" target=\"_blank\">ENOB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521777-enochian-bioplus-18-premarket-on-acquiring-exclusive-license-for-hbv\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Enochian Bio +18% premarket on acquiring exclusive license for HBV</a></h4><ul> <li>Enochian Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ENOB' title='Enochian Biosciences Inc.'>ENOB</a>) is up <font color=\"green\">18%</font> premarket on <a href=\"https://seekingalpha.com/pr/17709573-enochian-biosciences-expands-infectious-disease-pipeline-entering-agreement-principle-acquire\" target=\"_blank\">entering</a> into an agreement in principle to acquire an exclusive license for a treatment under development aimed to treat the Hepatitis B Virus &#40;HBV&#41; infections from G-Tech Bio, LLC.</li>  <li>Enochian licenses are for intellectual property that include proprietary know-how and pending patent applications covering aspects of our pipeline therapeutics.</li>  <li>Enochian has recently entered into agreements that will provide an additional $12M in funding.</li><li>Also, an abstract accepted for presentation at the HepDART meeting featuring <em>in vivo</em> and <em>in vitro</em> data from preclinical studies conducted with this HBV treatment candidate will be presented on December 10.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3521777\" data-linked=\"Enochian Bio +18% premarket on acquiring exclusive license for HBV\" data-tweet=\"$ENOB - Enochian Bio +18% premarket on acquiring exclusive license for HBV https://seekingalpha.com/news/3521777-enochian-bioplus-18-premarket-on-acquiring-exclusive-license-for-hbv?source=tweet\" data-url=\"https://seekingalpha.com/news/3521777-enochian-bioplus-18-premarket-on-acquiring-exclusive-license-for-hbv\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521776\" data-ts=\"1574690682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ENR\" target=\"_blank\">ENR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521776-energizer-shakes-off-jpmorgans-bear-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energizer shakes off JPMorgan&#39;s bear call</a></h4><ul> <li>JPMorgan hikes Energizer Holdings (NYSE:<a href='https://seekingalpha.com/symbol/ENR' title='Energizer Holdings, Inc.'>ENR</a>) to a Neutral rating from Underweight after taking in the company's analyst day presentation.</li> <li>\"While management discussed their leading positions across batteries and auto care, the importance of brands, and having a portfolio that fits consumer needs across the value spectrum, we felt there was a particular emphasis on both innovation and brand investment throughout the presentations at the analyst day. We came away encouraged by some of the company\u2019s initiatives and believe their focus on innovation and brand investment can help lead to relative outperformance going forward.\"</li> <li>JP's price target of $51 on Energizer is based off a 50-50 blend of the 2021 EPS estimate of 14X and EV/EBITDA multiple of 9.5X. The average sell-side PT on Energizer is <a href=\"https://seekingalpha.com/symbol/ENR/ratings/sell-side-ratings\" target=\"_blank\">$56.17</a>.</li> <li>Shares of Energizer are <font color=\"green\">up 0.46%</font> premarket to $50.44.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521776\" data-linked=\"Energizer shakes off JPMorgan&#39;s bear call\" data-tweet=\"$ENR - Energizer shakes off JPMorgan&#39;s bear call https://seekingalpha.com/news/3521776-energizer-shakes-off-jpmorgans-bear-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3521776-energizer-shakes-off-jpmorgans-bear-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521770\" data-ts=\"1574690003\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SOL\" target=\"_blank\">SOL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521770-renesola-names-new-ceo-cfo-after-departures\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ReneSola names new CEO, CFO after departures</a></h4><ul><li>ReneSola (NYSE:<a href='https://seekingalpha.com/symbol/SOL' title='ReneSola Ltd'>SOL</a>) says CEO Shelley Xu has <a href=\"https://seekingalpha.com/pr/17709605-renesola-announces-management-transition\" target=\"_blank\">left the company</a>, to be replaced by former Canadian Solar executive Yumin Liu, effective Dec. 4; Xu had been CEO only since July.</li><li>SOL also names Ke Chen as its new CFO, effective immediately, while remaining on the company's board; Xiaoliang Liang, who became CFO in June 2018, also has left the company.</li><li>Liu has more than 20 years of experience in energy management, power generation and solar technology, most recently as VP of the EMEA region at Canadian Solar; previously he was President of Recurrent Energy, a U.S. subsidiary of Canadian Solar.</li><li>SOL <font color=\"green\">+3.1%</font> pre-market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521770\" data-linked=\"ReneSola names new CEO, CFO after departures\" data-tweet=\"$SOL - ReneSola names new CEO, CFO after departures https://seekingalpha.com/news/3521770-renesola-names-new-ceo-cfo-after-departures?source=tweet\" data-url=\"https://seekingalpha.com/news/3521770-renesola-names-new-ceo-cfo-after-departures\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521768\" data-ts=\"1574689839\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521768-adamis-pharmaminus-61-on-fdas-zimhi-rejection\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamis Pharma -61% on FDA&#39;s Zimhi rejection</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17709764-adamis-pharmaceuticals-receives-complete-response-letter-fda-regarding-zimhi\" target=\"_blank\">rejects</a> Adamis Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corporation'>ADMP</a>) opioid overdose treatment.</li><li>In a letter to the company, the FDA cited concerns about Zimhi's chemistry and manufacturing but not the safety or efficacy.</li><li>Adamis plans to expand on the chemistry, manufacturing, and controls testing to satisfy the items in the FDA's Complete Response Letter.</li><li>ADMP shares <font color=\"red\">plunge 61%</font> pre-market to $0.49.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521768\" data-linked=\"Adamis Pharma -61% on FDA&#39;s Zimhi rejection\" data-tweet=\"$ADMP - Adamis Pharma -61% on FDA&#39;s Zimhi rejection https://seekingalpha.com/news/3521768-adamis-pharmaminus-61-on-fdas-zimhi-rejection?source=tweet\" data-url=\"https://seekingalpha.com/news/3521768-adamis-pharmaminus-61-on-fdas-zimhi-rejection\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521766\" data-ts=\"1574689342\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CGC\" target=\"_blank\">CGC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521766-canopy-growthplus-4-premarket-on-new-cannabis-license-for-smiths-falls-facility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Canopy Growth +4% premarket on new cannabis license for Smiths Falls facility</a></h4><ul> <li>Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) has <a href=\"https://seekingalpha.com/pr/17709810-canopy-growth-receives-health-canada-licence-state-art-beverage-facility\" target=\"_blank\">received</a> its operating and secure storage licence from Health Canada for its 150,000 sq. ft. beverage facility located at Smiths Falls, ON.</li>                   <li>Eleven beverages, all based on the company's unique Distilled Cannabis process, will be produced in the Smiths Falls facility.</li><li>Shares are up <font color=\"green\">4%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521766\" data-linked=\"Canopy Growth +4% premarket on new cannabis license for Smiths Falls facility\" data-tweet=\"$CGC - Canopy Growth +4% premarket on new cannabis license for Smiths Falls facility https://seekingalpha.com/news/3521766-canopy-growthplus-4-premarket-on-new-cannabis-license-for-smiths-falls-facility?source=tweet\" data-url=\"https://seekingalpha.com/news/3521766-canopy-growthplus-4-premarket-on-new-cannabis-license-for-smiths-falls-facility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521762\" data-ts=\"1574688885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGE\" target=\"_blank\">TGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521762-tallgrass-energy-ceo-dehaemers-departs-succeeded-moler\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tallgrass Energy CEO Dehaemers departs, succeeded by Moler</a></h4><ul><li>Tallgrass Energy (NYSE:<a href='https://seekingalpha.com/symbol/TGE' title='Tallgrass Energy, LP'>TGE</a>) <font color=\"red\">-2.6%</font> pre-market following news that CEO David Dehaemers is retiring and <a href=\"https://seekingalpha.com/pr/17709513-tallgrass-energy-announces-ceo-succession-plan\" target=\"_blank\">stepping down as CEO</a> effective immediately; he will retire from the board at year's end.</li><li><a href=\"https://seekingalpha.com/news/3512123-tallgrass-ceo-defends-provisions-management-blackstone-deal\" target=\"_blank\">Dehaemers had been criticized</a> over sales talks with P-E firm Blackstone Infrastructure Partners, whose August non-binding offer to buy TGE shares it did not already own for  $19.50 each included a provision for management to be paid a ~30%  premium for shares in the general partner that owns TGE.</li><li>Dehaemers was co-founder, CEO and Chief Investment Officer of Tallgrass MLP Fund during 2008-12, has been a director and CEO of TGE's general partner since 2015 as well as President until March 2019; he was executive VP of corporate development at Inergy LP during 2003-07.</li><li>Moler has been a director of TGE's general partner since 2015 and served as executive VP and COO until becoming President and COO this March; from 2004 until his departure in 2012, Moler had served in various capacities with Inergy LP and its affiliates.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521762\" data-linked=\"Tallgrass Energy CEO Dehaemers departs, succeeded by Moler\" data-tweet=\"$TGE - Tallgrass Energy CEO Dehaemers departs, succeeded by Moler https://seekingalpha.com/news/3521762-tallgrass-energy-ceo-dehaemers-departs-succeeded-moler?source=tweet\" data-url=\"https://seekingalpha.com/news/3521762-tallgrass-energy-ceo-dehaemers-departs-succeeded-moler\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521758\" data-ts=\"1574688727\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JD\" target=\"_blank\">JD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521758-new-jd-com-bull-praises-acceleration-margin-profile\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New JD.com bull praises acceleration, margin profile</a></h4><ul><li>Barclays upgrades JD.com (NASDAQ:<a href='https://seekingalpha.com/symbol/JD' title='JD.com, Inc.'>JD</a>) from Equal-Weight to Overweight, citing a more positive view of the Chinese e-commerce sector.</li><li>Analyst Gregory Zhao notes the sector's \"very robust\" Singles' Day GMV growth, which \"bodes well\" for Q4 results.</li><li>Zhao praises JD's accelerating user and revenue growth and its \"solid\" margin profile.</li><li>Barclays raises its JD.com target by $2 to $38.</li><li>JD shares are <font color=\"green\">up 2.2%</font> pre-market to $32.64.</li><li>The company has a Bullish average <a href=\"https://seekingalpha.com/symbol/JD/ratings/sell-side-ratings\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521758\" data-linked=\"New JD.com bull praises acceleration, margin profile\" data-tweet=\"$JD - New JD.com bull praises acceleration, margin profile https://seekingalpha.com/news/3521758-new-jd-com-bull-praises-acceleration-margin-profile?source=tweet\" data-url=\"https://seekingalpha.com/news/3521758-new-jd-com-bull-praises-acceleration-margin-profile\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521751\" data-ts=\"1574687775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CBAY\" target=\"_blank\">CBAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521751-cymabay-halts-trial-of-seladelpar-shares-dip-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CymaBay halts trial of seladelpar; shares dip 4%</a></h4><ul><li>\"The decision to halt development of seladelpar was based on initial histological findings observed in the Phase 2b study of seladelpar in NASH,\" <a href=\"https://seekingalpha.com/pr/17709754-cymabay-therapeutics-halts-clinical-development-seladelpar\" target=\"_blank\">says the company</a>, noting histology characterized as an interface hepatitis presentation, with or without biliary injury.</li><li>A conference call is set for 4:30 PM ET.</li><li><a href='https://seekingalpha.com/symbol/CBAY' title='CymaBay Therapeutics, Inc.'>CBAY</a> <font color=\"red\">-4%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3521751\" data-linked=\"CymaBay halts trial of seladelpar; shares dip 4%\" data-tweet=\"$CBAY - CymaBay halts trial of seladelpar; shares dip 4% https://seekingalpha.com/news/3521751-cymabay-halts-trial-of-seladelpar-shares-dip-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3521751-cymabay-halts-trial-of-seladelpar-shares-dip-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521748\" data-ts=\"1574687431\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521748-luxury-sector-shakeup-sends-investors-scrambling\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Luxury sector shakeup sends investors scrambling</a></h4><ul> <li>Tiffany (NYSE:<a href='https://seekingalpha.com/symbol/TIF' title='Tiffany & Co.'>TIF</a>) is <font color=\"green\">up 5.69%</font> premarket to $132.65 after striking a buyout deal with LVMH(<a href='https://seekingalpha.com/symbol/LVMHF' title='LVMH Moët Hennessy - Louis Vuitton, Société Européenne'>OTCPK:LVMHF</a>) at $135 per share. LVMH is <font color=\"green\">1.34% higher</font> in Paris trading.</li> <li>The $16.2B deal is expected to close next year. The acquisition still needs to be approved by Tiffany shareholders.</li> <li>Analysts note the Tiffany deal gives LVMH a much larger presence in the U.S. and will boost the jewelry and watches businesses,</li> <li>In London, shares of Burberry (<a href='https://seekingalpha.com/symbol/BURBY' title='Burberry Group plc'>OTCPK:BURBY</a>) are <font color=\"green\">up 2.85%</font> following the luxury sector shakeup.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3521673-lvmh-reaches-deal-tiffany\" target=\"_blank\">LVMH reaches deal for Tiffany</a> (Nov. 24)</li></ul><div class=\"tiny-share-widget\" data-id=\"3521748\" data-linked=\"Luxury sector shakeup sends investors scrambling\" data-tweet=\"$TIF $LVMHF $BURBY - Luxury sector shakeup sends investors scrambling https://seekingalpha.com/news/3521748-luxury-sector-shakeup-sends-investors-scrambling?source=tweet\" data-url=\"https://seekingalpha.com/news/3521748-luxury-sector-shakeup-sends-investors-scrambling\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521742\" data-ts=\"1574687052\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521742-loop-turns-bullish-on-snap-ad-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Loop turns bullish on Snap ad growth</a></h4><ul><li>Loop Capital upgrades Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) from Hold to Buy and increases the target by $5 to $20.</li><li>The firm cites strong ad revenue growth and user engagement improvement over the recent quarters.</li><li>SNAP shares are<font color=\"green\"> up 1.6%</font> pre-market to $15.50.</li><li>Snap has a Bullish average <a href=\"https://seekingalpha.com/symbol/SNAP/ratings/sell-side-ratings?s=snap\" target=\"_blank\">Sell Side rating</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521742\" data-linked=\"Loop turns bullish on Snap ad growth\" data-tweet=\"$SNAP - Loop turns bullish on Snap ad growth https://seekingalpha.com/news/3521742-loop-turns-bullish-on-snap-ad-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3521742-loop-turns-bullish-on-snap-ad-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521736\" data-ts=\"1574686429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAS\" target=\"_blank\">HAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521736-hasbro-gains-after-ubs-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hasbro gains after UBS upgrade</a></h4><ul> <li>UBS raises Hasbro (NASDAQ:<a href='https://seekingalpha.com/symbol/HAS' title='Hasbro, Inc.'>HAS</a>) to a Buy rating on a valuation call.</li> <li>The firm sees more than 20% upside for the toy stock on its view Hasbro's cost synergies from the eOne deal and gaming portfolio momentum aren't being appreciated by investors.</li> <li>UBS assigns a price target of $117 to Hasbro vs. the sell-side average PT of <a href=\"https://seekingalpha.com/symbol/HAS/ratings/sell-side-ratings\" target=\"_blank\">$113.00</a>.</li> <li>Shares of Hasbro are <font color=\"green\">up 1.35%</font> premarket to $97.41.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521736\" data-linked=\"Hasbro gains after UBS upgrade\" data-tweet=\"$HAS - Hasbro gains after UBS upgrade https://seekingalpha.com/news/3521736-hasbro-gains-after-ubs-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3521736-hasbro-gains-after-ubs-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521728\" data-ts=\"1574685530\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WBK\" target=\"_blank\">WBK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521728-westpac-falls-again-heat-intensifies\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Westpac falls again as heat intensifies</a></h4><ul> <li>Westpac Banking Corporation (NYSE:<a href='https://seekingalpha.com/symbol/WBK' title='Westpac Banking Corporation'>WBK</a>) is under <a href=\"https://www.theguardian.com/australia-news/2019/nov/25/westpac-in-crisis-talks-with-largest-investors-amid-money-laundering-scandal\" target=\"_blank\">investigation</a> for \"millions\" of violations of money laundering laws.</li> <li>Westpac so far has resisted calls from politicians for senior executives to be fired.</li> <li>Westpac is reportedly holding crisis talks with its largest institutional investors after taking on another ratings agency downgrade.</li> <li>Shares of Westpac fell another <font color=\"red\">1.33%</font> today in Sydney.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3521728\" data-linked=\"Westpac falls again as heat intensifies\" data-tweet=\"$WBK - Westpac falls again as heat intensifies https://seekingalpha.com/news/3521728-westpac-falls-again-heat-intensifies?source=tweet\" data-url=\"https://seekingalpha.com/news/3521728-westpac-falls-again-heat-intensifies\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3521723\" data-ts=\"1574684941\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRNE\" target=\"_blank\">SRNE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3521723-sorrento-received-rejected-unsolicited-acquisition-proposal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sorrento received, rejected unsolicited acquisition proposal</a></h4><ul><li>Sorrento Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SRNE' title='Sorrento Therapeutics, Inc.'>SRNE</a>) <font color=\"green\">+50.6%</font> pre-market after saying it <a href=\"https://seekingalpha.com/pr/17709586-sorrento-therapeutics-inc-received-rejected-unsolicited-cash-acquisition-proposal\" target=\"_blank\">rejected</a> an unsolicited  buyout proposal from two unnamed biopharma companies for $3.00-$5.00/share  in cash.</li><li>SRNE's board determined that the offer significantly undervalued the company and was not in the best interest of shareholders.</li><li>SRNE says it is in active late-stage licensing and collaboration  discussions with leading biopharma companies for its  immuno-oncology products, and believes the pending  transactions alone represent potential value  creation that significantly exceeds the proposal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3521723\" data-linked=\"Sorrento received, rejected unsolicited acquisition proposal\" data-tweet=\"$SRNE - Sorrento received, rejected unsolicited acquisition proposal https://seekingalpha.com/news/3521723-sorrento-received-rejected-unsolicited-acquisition-proposal?source=tweet\" data-url=\"https://seekingalpha.com/news/3521723-sorrento-received-rejected-unsolicited-acquisition-proposal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>32&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}